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Background:	 Obesity	 is	 a	 known	 risk	 factor	 for	 knee	 osteoarthritis	 (OA).	 It	 is	 speculated	 that	
adipokines	produced	by	excess	adipose	tissue	can	trigger	a	 low	grade	 inflammatory	state	 that	





To	 relate	 these	 factors	 with	 evaluation	 of	 clinical	 function,	 radiological	 status	 and	 circulating	
inflammatory	markers	of	the	patients.	
	
Methods:	 A	 total	 of	 114	 gender-matched	participants	were	 recruited	 into	 three	equal	 groups	
(n=38):	non-obese	 (Md	age	=	74.00	+/-	36.00	years),	obese	 (Md	age	=	62.00	+/-	46.00	years),	
and	metabolic	syndrome	(MetS)	(Md	age	=	71.50	+/-	38.00	years).	Clinical	parameters	included	
other	 joints	 involved	 with	 OA;	 patient	 reported	 outcome	 measures	 (WOMAC,	 SF-12);	 OA	
Kellgren-Lawrence	grading;	 and	blood	plasma	 leptin,	 apelin,	 progranulin	 and	S100A8/A9	were	
analysed	via	enzyme-linked	immunosorbent	assay	technique.		
	












Conclusions:	 Plasma	 leptin,	was	 strongly	 correlated	with	 BMI	 levels	 unlike	 plasma	 apelin	 and	
progranulin.	 The	 findings	 indicated	 that	 raised	 leptin	 concentrations	 was	 associated	 with	
reduced	general	health	whilst	the	opposite	was	seen	for	plasma	apelin.	An	 increased	systemic	
progranulin	 was	 associated	 with	 reduced	 inflammation,	 perhaps	 demonstrating	 a	 protective	




No	 portion	 of	 the	 work	 referred	 to	 in	 the	 thesis	 has	 been	 submitted	 in	 support	 of	 an	





Biobank,	 produced	 during	 my	 time	 at	 the	 Department	 of	 Molecular	 and	 Clinical	 Cancer	
Medicine,	 University	 of	 Liverpool,	 between	 August	 2014	 and	 July	 2017.	 The	 thesis	 was	
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Osteoarthritis	 (OA)	 is	 a	 long	 standing	 deleterious	 joint	 disease.	 It	 is	 represented	 by	 the	
ongoing	 injury	 and	 attempted	 repair	 of	 articular	 cartilage	 and	 subchondral	 bone	 (1).	 Not	
only	 that,	 OA	 also	 causes	 injury	 to	 the	 soft	 tissues	 which	 include	 the	 meniscus	 and	
ligaments,	development	of	osteophytes	as	well	as	the	intermittent	appearance	of	synovitis	




Being	 one	 of	 the	 oldest	 known	 diseases	 with	 a	 substantial	 prevalence	 (4,	 5)	 in	 the	
population,	 certainly,	 OA	 is	 a	 condition	 that	 requires	 an	 exceptional	 consideration	 in	 the	
pursuit	for	an	alternative	treatment	other	than	surgical	 intervention.	 It	has	been	regarded	




Of	 all	 the	 joints	 in	 the	 body,	 the	 knee	 joints	 are	 more	 commonly	 impacted	 by	 OA.	 The	
evidence	is	well	supported	by	epidemiological	studies	that	are	carried	out	nationwide	across	
various	 ethnic	 backgrounds	 (8-10).	 Indeed,	 there	 are	multiple	 factors	 that	 are	 involved	 in	
the	pathogenesis	of	knee	OA	that	include	age,	gender	and	obesity	(11,	12).		
	
Obesity	 has	 been	 accepted	 as	 one	 of	 best-established	 modifiable	 elements	 in	 knee	 OA.	
Considerable	amount	of	mechanical	stress	is	subjected	onto	the	joint	surface	which	leads	to	








dyslipidaemia	 and	 insulin	 resistance.	 Nowadays,	 this	 is	 known	 as	 Metabolic	 syndrome	
(MetS)	 (15).	 Hence,	 people	who	 are	 diagnosed	with	MetS	 not	 only	 have	 a	 higher	 risk	 of	
developing	 knee	OA,	 but	 they	 also	have	 a	 greater	 risk	 of	 developing	heart	 attack,	 stroke,	
type	2	diabetes	and	death	(16).	
	
Notably,	 researchers	 who	 have	 conducted	many	 epidemiological	 surveys	 discovered	 that	
obese	individuals	have	a	tendency	to	develop	OA	in	their	non-weight	bearing	joints	such	as	
the	hands	and	wrists	joints	(10,	17).	In	this	context,	this	shows	that	mechanical	stress	is	not	
the	 only	 explanation	 for	 its	 occurrence.	 For	 this	 reason,	 a	 unique	 concept	 emerges	
suggesting	 that	 excess	 fat/adipose	 tissue	 can	 give	 rise	 to	 a	 low	 grade	 inflammatory	 state	






modulating	 immune,	 nervous	 and	 cardiovascular	 systems	 (19).	 As	 more	 evidence	
accumulates,	 confirming	 the	 adipokines’	 critical	 actions	 towards	 the	 overall	 health,	
increasing	 efforts	 and	 investigations	 have	 been	 steered	 into	 the	 scientific	 journey	 to	
scrutinise	 adipokines	 further.	 Therefore,	 it	 is	 our	 intention	 to	 determine	 the	 metabolic	
connection	between	knee	OA,	obesity	and	metabolic	syndrome.	
	




degrade	 articular	 cartilage	 (21).	 Leptin	 can	 also	 assist	 in	 the	 formation	 of	 osteophytes,	
another	fundamental	feature	of	OA	(22).	
	




macrophage	 aggregation	 in	 vascular	 inflammation	 (24).	 However,	 apelin	 resembles	 leptin	
activity	 when	 it	 is	 studied	 on	 the	 musculoskeletal	 system.	 Studies	 showed	 that	 apelin	
motivates	 pro-inflammatory	 factors	 that	 can	disintegrate	 articular	 cartilage	 and	promotes	
osteophyte	formation	(25,	26).	
	
The	 final	novel	 adipokine	of	 interest	 is	Progranulin	 (PGRN),	which	has	made	a	mark	 in	 its	
successful,	anti-inflammatory	duty	against	rheumatoid	arthritis.	It	was	originally	involved	as	
an	 important	 protein	 that	 counteract	 against	 neurodegenerative	 diseases	 such	 as	
Parkinson’s,	 Alzheimer’s	 and	 Creutzfeldt-Jakob	 diseases	 (27,	 28).	 Later	 on,	 it	 has	
demonstrated	 a	 remarkable	 anti-inflammatory	 action	 in	 several	 other	 conditions	 such	 as	














OA	 is	 the	 leading	 form	 of	 arthritis	 and	 the	 number	 one	 foremost	 reason	 for	 disability	 in		
senior	residents	(6).	It	ranks	as	the	ninth	greatest	reason	in	low-	and	middle-income	nations,	
and	the	fifth	greatest	source	of	years	given	up	to	disability	in	the	entire	population	of	high-
income	nations	 (35).	 In	 2012,	 it	was	 reported	 in	 the	Global	 Burden	of	Disease	 Study	 that	
musculoskeletal	conditions	accounted	for	approximately	6.8%	of	the	disability-adjusted	life	
years	 (36).	 This	 indicates	 that	 OA	 and	 other	 musculoskeletal	 disorders	 are	 exceptionally	
prevalent	in	all	population.	Owing	to	this	fact,	OA	has	been	chosen	during	the	World	Health	




is	anticipated	to	 increase	and	 it	will	create	a	huge	burden	on	the	 lifestyle	and	health	care	
costs	 (5,	7).	 In	developed	countries,	most	 individuals	with	symptomatic	OA	have	access	to	










and	above.	 This	has	been	 identified	as	 the	main	 source	of	disability	 justifying	 for	 about	a	
third	 of	 all	 years	 lived	 with	 disability	 (7,	 41).	 In	 2002,	 the	 Arthritis	 Research	 Council	 UK	
	 5	
evaluated	 that	 no	 less	 than	 4.4	million	 individuals	 had	 x-ray	 proof	 of	moderate-to-severe	







in	 constant	 pain	 or	 had	 limitation	 in	 performing	 everyday	 tasks	 (43).	 OA	 treatment	 also	
carries	a	huge	cost	burden	to	the	NHS	and	the	society.	A	fifth	of	the	population	consult	their	
general	 practitioner	 about	 a	musculoskeletal	 condition	 and	 this	 constitutes	 over	 100,000	















dinosaurs	bony	structures,	Egyptian	mummies	and	human	bones	unearthed	 in	 the	UK	 (4).	
Regardless	of	its	predominance	in	the	past,	up	until	now,	the	aetiology	is	still	not	thoroughly	










in	60%	of	males	and	70%	of	 females	over	65	years	of	age	 (50).	As	primary	OA	 is	not	 fully	
understood,	 there	 are	 no	 current	 therapeutic	 treatments	 or	 interventions	 to	 restore	
degenerate	 cartilage	or	 slow	down	 the	progression	of	OA	 (49).	 Therefore,	we	attempt	 to	






















Nowadays,	 OA	 is	 recognised	 as	 a	wear	 and	 tear	 condition	 and	 is	 not	 an	 isolated	 disease	
entity.	 In	 fact,	 it	 is	 a	 combination	of	 various	 disease	 processes	 having	 several	 risk	 factors	
(Figure	 1).	 The	 risk	 factors	 can	 be	 divided	 into	 endogenous	 and	 exogenous	 components.	
Endogenous/non-modifiable	parameters	are	older	age,	female	gender,	genetic	inheritance,	
ethnic	 origin	 and	 post-menopausal	 changes.	 Exogenous/modifiable	 factors	 are	 macro-
trauma,	repetitive	micro-trauma,	overweight,	resective	joint	surgery,	bone	density,	muscle	
weakness,	 kneeling/squatting	 and	 lifestyle	 factors	 (alcohol/	 tobacco	 use)	 (11,	 12).	 The	









The	 articular	 cartilage	 is	 made	 up	 of	 cells,	 predominantly	 chondrocytes,	 embedded	 in	
extracellular	matrix	 derived	 from	multiple	 types	of	 collagen.	 It	 receives	 its	 nutrients	 from	





joint	 as	 well	 as	 facilitate	movement.	 It	 has	many	 properties	 to	 optimize	 its	 load	 bearing	




At	 the	 cellular	 level,	 the	 degenerative	 changes	 in	 OA	 occur	 with	 a	 local	 inflammatory	
element	that	may	instigate	and	accelerate	joint	destruction.	Several	inflammatory	factors	in	
particular,	 IL-1ß,	 IL-6	 and	 TNF-α	 are	 regularly	 implicated	 in	 the	 pathogenesis	 of	OA	 along	
with	 MMP-3	 and	 MMP-13	 (53,	 54).	 As	 a	 result	 of	 inflammation	 and	 ongoing	 oxidative	
damage,	 a	 vicious	 cycle	 takes	 place	 in	 the	 diseased	 joint.	 Alteration	 in	 the	
immunomodulatory	 and	 inflammatory	 mediators	 cause	 the	 chondrocytes	 to	 produce	






chondrocytes	 proliferation	 laying	 out	 new	extracellular	matrix	 (ECM)	 that	 includes	 type	 II	
collagen	fibrils	and	proteoglycans.	This	is	a	response	to	the	insult	and	an	attempt	to	repair	
the	 damage.	 However,	 this	 process	 becomes	 insufficient	 with	 an	 ongoing	 mechanical	
damage	 leading	 to	 ECM	degradation;	 thus,	 irreversible	OA	develops	 (56).	Microscopically,	




The	 degraded	 particles	 from	 cartilage	 ECM	 are	 liberated	 into	 the	 synovial	 fluid	 and	 are	
phagocytosed	 by	 the	 synovial	 macrophages.	 As	 a	 consequence,	 they	 release	 more	 pro-
inflammatory	cytokines	like	IL-1ß	that	have	the	ability	to	activate	other	proteases	to	further	
break	down	the	cartilage	(57).	This	process	is	also	accompanied	by	synovial	hyperplasia	and	
hypertrophy.	 This	 is	 believed	 to	 be	 a	 central	 cause	 of	 pain	 experienced	 by	 osteoarthritic	
individuals	 as	 increased	 innervation	 in	 the	 joint	 is	 associated	 with	 synovial	 inflammation	
(57).	
	
In	 the	 later	 stages	 of	 OA,	 an	 important	 characteristic	 feature	 of	 OA	 is	 the	 formation	 of	
osteophytes.	 Osteophytes	 are	 bony	 spurs	 that	 are	 formed	 at	 the	 joint	 margins,	 as	 an	
evidence	 of	 attempted	 repair	 in	 response	 to	 the	 degenerating	 cartilage,	 disappearing	
surface	area	and	 the	ongoing	 joint	 instability.	 It	 is	 thought	 that	 the	biomechanical	 stimuli	
lead	the	proliferation	of	the	mesenchymal	cells	in	the	synovium	and	periosteum	to	undergo	
chondrogenesis	 under	 the	 effect	 of	 growth	 factors,	 such	 as	 Transforming	 Growth	 Factor	
(TGF)-ß	 and	 Bone	 Morphogenetic	 Proteins	 (BMPs)	 (58).	 However,	 their	 functional	 use	 is	
rather	contentious	as	they	are	generally	found	on	the	non-weight	bearing	areas.		
	
When	 a	 healthy	 articular	 cartilage	 is	 designated	 to	 bear	 stress	 and	 deform	 on	 loading,	
osteoarthritic	 tissue	 is	unable	 to	 function	properly	 leading	to	permanent	deformation	and	
stress	 transfer	 to	 the	 underlying	 bone.	 The	 subchondral	 bone,	 in	 turn,	 is	 forced	 to	 bear	
greater	loads	beyond	its	yield	point	causing	a	permanent	deformation	or	ultimate	failure	of	






















Individuals	with	 knee	OA	 frequently	 experience	 joint	 pain	 at	 rest	 and	worse	 on	 exercise.	
They	also	complain	of	grinding	mechanical	sensation	on	moving	the	affected	joint.	Stiffness	
is	often	temporary	(less	than	30	minutes)	when	compared	to	inflammatory	arthritis	where	it	





grooming	 and	 driving	 a	 car.	 Pain	 suffered	 can	 be	 severe	 enough	 up	 to	 a	 stage	 where	 it	
disturbs	sleep	(64).	On	physical	examination,	knee	OA	individuals	commonly	show	deformity	
of	 the	 lower	 limb	 accompanied	 by	 alteration	 of	 bony	 contours,	 variable	 swelling	 with	
effusion,	tenderness	at	 joint	 line,	 limited	range	of	movement	with	crepitus	and	occasional	
sign	of	instability.	
	
Clinical	 knee	 OA	 can	 be	 diagnosed	 using	 the	 American	 College	 of	 Rheumatology	 criteria	
(Figure	2)	(65).	It	is	divided	into	major	and	minor	inclusion	criteria.	Joint	pain	for	majority	of	
the	 days	 in	 the	 preceding	 month	 is	 considered	 a	 major	 inclusion	 criterion.	 Other	 minor	




rheumatoid	 factor	not	more	 than	1:40.	 In	addition	 to	 the	only	major	 criterion,	5	of	 the	9	
minor	criteria	must	be	met	before	diagnosis	can	be	reached.	Alternatively,	knee	OA	can	be	
diagnosed	in	accordance	to	clinical	and	radiographic	criteria.	The	main	criterion	is	knee	pain	





Of	all	 the	parameters,	knee	pain	 is	 the	most	 important	 factor	that	can	trigger	a	decline	 in	
physical	 function	resulting	 in	 lifestyle	modification	(66).	A	vicious	cycle	will	begin	whereby	
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those	 affected	 revealed	 a	 drop	 in	 overall	 physical	 conditioning	 and	 an	 increase	 in	 body	





Plain	 radiography	continues	 to	be	 the	mainstay	 in	 the	diagnosis	of	OA.	 Its	 severity	can	be	
further	 evaluated	 using	 the	 most	 commonly	 used	 system	 for	 grading	 OA,	 the	 Kellgren-
Lawrence	 (KL)	scale.	 It	 is	physician	based,	assessing	the	structural	changes	 inherent	 to	OA	






2=minimal	 OA	 characterized	 by	 possible	 joint	 space	 narrowing	 with	 definite	 osteophyte	
formation,	 3=moderate	 OA	 with	 definite	 joint	 space	 narrowing,	 moderate	 osteophyte	
formation,	some	subchondral	sclerosis	and	possible	bony	ends	deformity	and	4=severe	OA	













Grade	0	 None	 None	 None	 None	
Grade	1	 Doubtful	 Possible	 None	 None	
Grade	2	 Possible	 Definite	 None	 None	
Grade	3	 Definite	 Moderate	 Some	 Possible	
Grade	4	 Marked	 Large	 Severe	 Definite	
	
KL	scale	is	widely	used	in	the	Arthritis	Research	UK	and	has	been	validated	with	arthroscopic	
findings	 as	 well	 as	 proven	 to	 be	 reliable	 and	 reproducible	 (69,	 70).	 It	 may	 help	 medical	
professionals	 formulate	 a	management	 framework	 and	 assist	 in	making	 the	 right	 clinical	
choice	 in	 particular,	 delineating	which	 individuals	 likely	 to	 have	worse	 outcome	 and	may	
benefit	 from	 surgical	 treatment.	 Moreover,	 it	 can	 be	 used	 in	 data	 collection	 among	 the	




follows	 a	 continuous	 radiographic	 sequence	 of	OA	 starting	with	 osteophyte	 development	
followed	by	joint	space	narrowing	and	ending	with	articular	surface	deformity.	It	has	been	
criticised	 that,	 in	 some	 occurrences,	 patients	 present	 with	 radiographical	 evidence	 of	
cartilage	 loss	 without	 any	 visible	 osteophyte	 formation	 (72);	 thus,	 underestimating	 the	
severity	of	the	condition.	Another	limitation	to	KL	scale	is	the	failure	to	recognise	OA	of	the	
patellofemoral	 compartment	 as	 a	 clear,	 separate	 contributing	 radiographic	 change	 (68).	
Furthermore,	Gunther	and	Sun	underrated	the	reproducibility	of	KL	scale	describing	inferior	












two	 systems	 that	 perform	 together	 to	 achieve	homeostasis	with	 the	 aim	of	 repairing	 the	
host	body.	The	two	systems	are	the	innate	and	adaptive	immune	systems.	For	any	external	
or	 internal	 instigation,	our	 initial	 form	of	defence	 is	via	 the	 innate	 immune	system	(76).	 It	
possesses	 a	much	 broader	 action	 against	 these	 stimuli	 and	 also	 encourages	 the	 adaptive	
immune	 system	 to	 be	 activated.	 On	 the	 other	 hand,	 the	 adaptive	 immune	 system	 has	 a	
specific	 capability	 to	 initiate	 a	 defence	 action	 when	 the	 body	 is	 exposed	 to	 a	 particular	


























(DC)s	 (81).	 It	 can	 also	 be	 utilised	 to	 activate	 the	 signalling	 pathways	 which	 can	 lead	 to	
transcription	initiation	for	various	genes	responsible	for	immune	response	(82).	With	these	
strategies,	 the	 body	 can	 start	 an	 appropriate	 inflammatory	 reaction	 efficiently	 when	 it	
detects	non-self	molecules.		
	
Apart	 from	 infection	 and	 injury,	 inflammation	 can	 also	 be	 provoked	 by	 other	 obnoxious	
factors	 to	 the	body	such	as	 toxin,	autoimmune	damage,	as	well	as	post	 ischaemic	 injuries	
(74).	As	mentioned	earlier,	the	innate	immunity	is	stimulated	by	PAMPs	and	likewise,	it	can	
be	 switched	 on	 by	 other	 protein	 molecules	 as	 well	 such	 as	 Heat	 Shock	 Proteins,	
Neuropeptides,	HMGB1,	Histamines,	PGD2,	tryptases,	chemokines	and	TNF	(74).		
	




the	 inflammatory	 response	 activated	 for	 a	 long	 time,	 it	will	 not	 only	 destroy	 the	 harmful	
pathogens	 but	 at	 the	 same	 time	 can	 inflict	 collateral	 damage	 to	 the	 surrounding	 normal	
tissues.	 Therefore,	 to	 accomplish	 this	 goal,	 the	 host	 body	 has	 allocated	 ‘monitoring’	 cells	
such	 as	 mast	 cells	 and	 macrophages,	 that	 can	 reside	 in	 tissues	 and	 when	 they	 are	
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stimulated,	 they	 will	 produce	 molecules	 which	 can	 recruit	 more	 leukocytes	 from	 blood	
circulatory	system	(83).	
	
When	 there	 is	 an	 injury	 or	 invasion	 of	 pathogens	 to	 the	 body,	 the	mast	 cells	will	 at	 first	
detect	 them	and	start	 releasing	 its	pro-inflammatory	 factors.	Then,	 the	 factors	will	attract	
more	inflammatory	cells	to	arrive	at	the	problematic	site.	The	earliest	cells	to	arrive	are	the	
neutrophils;	 whose	 function	 is	 to	 magnify	 the	 inflammatory	 response	 as	 well.	 They	
stimulate	 more	 mast	 cells	 and	 produce	 chemotactic	 proteins	 for	 recruitment	 of	 more	
inflammatory	 cells.	 Another	 responsibility	 of	 neutrophils	 is	 to	 destroy	 the	 pathogens	 by	
liberating	enzymes	such	as	hydrolases	and	proteinases	as	well	as	unleashing	oxidants	such	









Another	 method	 that	 is	 activated	 as	 part	 of	 the	 inflammatory	 response	 is	 the	 adaptive	
immune	 system.	 This	 system	 employs	 a	 much	 more	 specialised	 and	 precise	 process	 in	
combination	with	the	innate	immune	system	with	the	purpose	of	removing	the	pathogenic	
focus	 and	 restoring	 haemostasis.	 To	 carry	 out	 this	 aim,	 the	 body	 weaponises	 itself	 with	





Adaptive	 immune	 system	 is	 very	 much	 reliant	 on	 antigen	 which	 is	 very	 exclusive	 to	 the	
pathogenic	particle	and,	unlike	the	innate	immunity,	this	system	retains	a	memory	of	it	(85).	
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As	a	consequence,	 it	warrants	 the	body	 to	 intensify	an	 immune	response	with	ease	 if	 the	
host	is	subjected	to	the	same	antigen	again.	However,	the	downside	of	being	very	specific	is	
the	 fact	 that	 there	 is	 a	 response	 delay	 between	 antigen	 detection	 and	 the	 optimal	
inflammatory	reaction,	usually	taking	a	few	days’	time.		
	
The	 T	 and	 B	 cells	 depend	 on	 the	 activity	 of	 the	 APCs	 before	 they	 start	 recognising	 a	
particular	 antigen.	Majority	 of	 the	 APCs	 are	 represented	 by	 DCs.	 However,	macrophages	
together	 with	 B	 cells	 and	 Langerhans	 cells	 are	 also	 known	 to	 behave	 like	 APCs	 (86).	 At	
present,	 it	 is	known	that	DCs	are	the	chief	regulatory	cells	 linking	the	 innate	and	adaptive	
immune	 systems	 in	 addition	 to	 polishing	 the	 activation	 of	 naïve	 T	 cells	 (87).	 The	 APCs	
capture	 the	 antigens,	 break	 them	 down	 and	 ‘present’	 the	 pathogenic	 molecules	 to	 the	
lymphocytes.	
	











Once	 the	 body	 has	 removed	 the	 pathogens/inflammatory	 stimulants,	 it	 will	 return	 to	 its	
normal	equilibrium.	However,	the	immune	system	will	not	cease	to	operate	but	continue	to	
be	 in	 alert	 mode	 monitoring	 for	 any	 stimulus	 available.	 Some	 stimuli	 that	 can	 spark	
inflammation	 may	 originate	 from	 the	 production	 of	 body’s	 harmful	 by-products	 such	 as	
glucotoxicity,	 lipotoxicity	 as	 well	 as	 inflammasomes	 activation	 (90).	 Therefore,	 the	 two	
immune	systems	adapt	the	above-mentioned	tactics	to	prevent	any	unnecessary	activation	
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In	 the	 last	 10	 years,	 there	 has	 been	 a	 gentle	 drift	 in	 our	 awareness	 on	 the	 primary	
pathogenesis	of	OA.	We	used	to	think	that	OA	develops	as	a	result	of	 inevitable	wear	and	
tear	 of	 the	 articular	 joint	 but	 nowadays,	 researchers/clinicians	 believe	 that	 individuals	
develop	 OA	 because	 they	 are	 exposed	 to	many	 predisposing	 factors	 that	 seem	 to	 utilise	
low-grade	and	chronic	inflammation	as	their	degradation	tool	(76).	
	
It	 is	speculated	that	the	chief	driving	mechanism	for	this	 form	of	 inflammatory	reaction	 is	
the	 activation	 of	 innate	 immune	 system	 rather	 than	 the	 adaptive	 immunity	 (48).	 As	
previously	discussed,	innate	immunity	generates	an	inflammatory	response	by	using	PRRs	to	
detect	 any	 PAMPs.	 Equivalent	 to	 this	 principle,	 PRRs	 are	 capable	 of	 detecting	 Damage-
Associated	Molecular	 Patterns	 (DAMP)s	 and	 initiate	 inflammation.	 DAMPs	 are	 molecules	
that	are	liberated	by	host	cells	as	a	response	to	stress	experienced	or	unplanned	cell	death	
(91).	 Sokolove	 et	 al	 stated	 that	 OA	 is	 affiliated	 to	 several	 DAMPs	 such	 as	 degraded	
extracellular	 matrix	 (biglycan,	 fibronectin,	 low-molecular	 weight	 hyaluronic	 acid	 and	
tenascin	 D),	 intracellular	 alarmins	 (HMGB1,	 S100	 family),	 crystals	 (calcium	 phosphate,	
calcium	pyrophosphate	dehydrate,	uric	acid)	as	well	as	plasma	proteins	(alpha-1	and	alpha-2	
microglobulin,	 fibrinogen,	 vitamin	 D-binding	 protein)	 leaking	 out	 from	 the	 circulatory	
system	(92).		
	
Another	 credible	 evidence	 supporting	 the	 involvement	 of	 innate	 immunity	 are	 the	
implication	 of	 macrophages	 and	 mast	 cells	 in	 OA	 development	 (93,	 94).	 Stimulated	
macrophages	are	seen	in	the	human	OA	synovium	and	they	secrete	cytokines	leading	to	the	
formation	 of	 osteophytes	 together	with	 cartilage	 disintegration	 (76).	 Likewise,	 stimulated	
mast	 cells	 are	 also	 found	 throughout	 the	 synovial	 lining	 of	 OA	 joints	 where	 positive	
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two	 set	 of	molecules	 from	 the	 S100	 family	which	 are	 S100A8	 and	 S100A9.	 They	 are	 also	
identified	as	myeloid-related	proteins	(MRP)	8	and	14	or	calgranulins	A	and	B.	The	common	










origin	 such	 as	 monocytes,	 activated	 macrophages	 and	 neutrophils	 which	 can	 further	





In	 addition	 to	 this,	 S100A8/A9	 can	 bind	 to	 receptors	 for	 AGEs	 which	 can	 cause	 further	




Calprotectin	 is	 a	 recognised	 biomarker	 in	 many	 inflammatory	 rheumatic	 diseases	 that	
include	RA,	spondyloarthritis,	psoriatic	arthritis	and	gout	(103).	Moreover,	van	Lent	et	al	has	
suggested	 that	 calprotectin	 was	 involved	 in	 synovial	 activation	 and	 cartilage	 degradation	
during	 OA	 (104).	 With	 the	 synovial	 stimulation,	 this	 alarmin	 plays	 an	 important	 part	 in	
osteophyte	 formation	 by	 activating	 chondrogenesis	 (105).	 A	 study	 investigating	
chondrocytes	 in	OA	patients	demonstrated	an	up	regulation	of	multiple	catabolic	markers	
such	 as	 MMPs	 1,	 3,	 9	 and	 13;	 IL-6,	 IL-8	 and	 monocyte	 chemotactic	 protein	 1,	 hence,	
favouring	cartilage	disintegration	(106).	
	
However,	 recent	 findings	 by	Mahler	et	 al	 failed	 to	 prove	 any	 association	 in	 patients	with	
established	 knee,	 hip	 and	 hand	 OA	 (107).	 Another	 study	 performed	 by	 Catalan	 et	 al	
described	S100A8/A9	as	a	new	marker	 for	obesity	where	 they	 found	positive	 relationship	









these,	 no	 fewer	 than	 200	million	males	 and	 300	million	 females	were	 classified	 as	 obese	
(14).	In	recent	years,	the	UK	has	turn	into	a	nation	where	overweight	is	widespread	owning	
to	one	of	 the	 rapidly	growing	obesity	 rates	 in	 the	developed	countries.	 It	has	a	hefty	cost	
implication	 to	 the	 National	 Health	 Service	 (NHS)	 whereby	 it	 was	 predicted	 at	 up	 to	 £3.7	













Obesity	 is	 termed	by	the	WHO	as	an	exaggerated	adipose	tissue	build-up	that	may	 impair	
health	 (110).	Adipose	tissue	 (AT)	consists	of	mainly	 fat	cells	also	known	as	adipocytes	and	
preadipocytes	along	with	 its	neurovascular	structures	(111).	AT	can	be	grouped	 into	white	
adipose	 tissue	 (WAT)	 or	 brown	 adipose	 tissue	 (BAT)	 (Figure	 3).	 BAT	 is	 known	 to	 regulate	
body	temperature	via	releasing	cellular	heat	from	food	energy	(112).	As	for	WAT,	 its	main	
purpose	 was	 to	 reserve	 excess	 lipid	 when	 energy	 requirement	 is	 low	 and	 to	 react	 to	











[weight	 (kg)/height	 (m)2]	 (114).	Table	3	 shows	 the	adult	 classification	 system	according	 to	
the	WHO.	BMI	is	easily	analysed,	understandable	and	has	been	shown	to	be	a	suitable	proxy	
in	 the	 general	 population	 (115,	 116).	 However,	 it	 operates	 differently	 at	 different	 ages,	
gender	 and	 ethnicities	 (117,	 118).	 It	 cannot	 distinguish	 between	 fat	mass	 and	 lean	mass	











Another	alternative	 to	measure	adiposity	 is	waist	 circumference	 (WC).	 It	 correlates	 to	 the	
visceral	excess	adipose	tissue	accumulation	and	is	believed	to	be	more	metabolically	active	
compared	to	the	peripherally	located	adipose	tissue	(119).	In	1988,	the	National	Heart	Lung	
and	 Blood	 Institute	 collected	 data	 from	 Glasgow	 UK,	 indicated	 that	 waist	 circumference	
assessment	was	more	sensitive	than	BMI	alone	for	categorising	those	who	are	at	higher	risk	
of	poor	health	outcomes	(120,	121).	However,	sex-based	differential	distribution	does	occur	
which	dampen	 the	overall	 usefulness	 of	WC	where	males	 tend	 to	deposit	 their	 fat	 in	 the	















From	biomechanics	 point	 of	 view,	 obese	 individuals	 present	with	 a	 remarkable	 change	 in	
gait	 and	 joint	 loading	 (129).	 Notably,	 they	 also	 spend	 more	 time	 in	 stance	 phase	 which	
signifies	a	longer	time	spent,	placing	a	substantial	pressure	on	the	joint	(13).	For	a	person	to	
perform	a	 single	 stance	during	walking,	 the	 knee	 joint	 has	 to	 bear	 a	 load	 equivalent	 to	 a	
force	approximately	three	to	six	times	the	body	weight.	Therefore,	it	is	understandable	that	
obese	 individuals	report	more	knee	 joint	pain	when	walking	(127,	128).	Other	 factors	that	
have	 been	 proposed	 in	 the	 literature	 are	 the	 combination	 of	 aging,	 varus	 malalignment,	












inflammatory	 process	 precipitated	 by	 obesity	 (18).	 Growing	 evidence	 has	 attracted	much	
attention	 where	 adipose	 tissue	 is	 considered	 as	 a	 functional	 endocrine	 organ.	 It	 has	 an	
influence	to	alter	the	cardiovascular,	metabolic	as	well	as	having	a	direct	adverse	impact	on	





oxidative	 stress	 where	 ROS	 accumulation	 exists.	 This	 is	 because	 the	 rate	 of	 production	
exceeds	 the	 rate	 of	 antioxidant	 produced	 leading	 to	 insulin	 resistance	 and	microvascular	





who	were	 non-obese	 and	 exclusive	 of	 cardio	metabolic	 factors.	 As	 for	 those	with	 obesity	
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muscle strength are protective against the development 
and progression of OA in the setting of neutral align-
ment, whereas in the setting of malalignment, increased 
muscle strength might increase abnormal joint loading 
and facilitate disease progression.
In contrast to muscle mass, fat mass has been shown 
to have a clearly detrimental relationship with knee 
structure. Fat mass is greater in people with OA than 
in those without,34,38 and is predictive of loss of joint-
space width.38 In asymptomatic people, increased fat 
mass has been associated with increases in both cartilage 
defects13,24 and BML,13 both of which predict greater rates 
of cartilage loss11,21 and joint replacement in patients with 
OA.19,23 The metabolic mechanisms by which fat mass 
might impart a detrimental effect on knee structure, thus 
increasing the risk of OA, are discussed next.
Metainflammation 
The increased adipose tissue present in obesity exerts 
on the body an inflammatory and metabolically active 
effect termed metainflammation. Adipose tissue pro-
duces specialised cytokines—adipokines—as well as 
inflammatory cytokines. Leptin is an adipokine that 
seems to play an important part in the initiation of OA.40 
Leptin is found in synovial fluid, chondrocytes and 
osteophytes in osteoarthritic knees, with levels related 
to those of insulin-like growth factor 1 (IGF-1) and 
transforming growth factor β (TGF-β). In the leptin- 
impaired mouse model of OA, leptin has an integral 
role in fat-related disease pathogenesis; in the absence of 
leptin, obesity did not increase the prevalence of OA.41 
This finding is consistent with data from a community-
based population study, in which raised serum levels of 
leptin were independently associated with a reduction 
in cartilage volume.14
Although other adipokines, such as adiponectin 
and resistin, are also present in synovial fluid, their 
role in OA pathogenesis is less clear than for leptin.42 
Nevertheless, adipokines and cytokines might affect the 
integrity of articular cartilage, promoting cartilage loss 
and the development of OA. IL-6 production by adipose 
tissue was associated with increased risk of radiographic 
OA in women (n = 908),43 and increased cartilage loss in 
a community-based population study (n = 172).44
Proinflammatory cytokines produced by adipose 
tissue might have a role not only in the structural 
changes of OA, but also in the perception of pain. 
Proinflammatory cytokines can act as pain modula-
tors, and this effect might contribute to the high preva-
lence of musculoskeletal complaints in obese people.45,46 
Although this association has not been studied in people 
with knee OA, obesity and waist circumference, a marker 
of abdominal obesity, were greater in 109 women with 
chronic pain (fibromyalgia) compared with 46 healthy 
controls.47 Whereas body composition has not been 
examined in relation to knee pain, we and others have 
shown that increased fat mass, in particular abdomi-
nal obesity, is associated with both back and foot pain 
in people recruited to study the relationship between 
musculo skeletal conditions and obesity.48,49 Muscle mass, 
however, is not related to the severity of pain in these 
regions, including after adjustment for mental status.48,49 
These findings suggest that pain perception is altered by 
systemic factors associated with obesity, and is likely to 
contribute to the experience of knee OA.
Obesity and OA: risk factors aligned 
As we have discussed, heterogeneous factors under-
lie the relationship between obesity and OA. In some 
indivi duals, the presence of malalignment combined 
with obesity increases the risk of OA, probably owing to 
a combination of biomechanical factors and metabolic 
inflammation, through which the cartilage and bone are 
more susceptible to injury by loading (Figure 1). That 
multiple factors are required for disease initiation is sup-
ported by the leptin-impaired mouse model of OA, in 
which intact leptin signalling was required for OA initia-
tion.41 Similarly, loading alone was inadequate for disease 
initiation in C57BL/6J mice.50 Nevertheless, our group 
has shown an increased prevalence of BML with increas-
ing BMI, in a population-based cohort study in 142 
healthy, asymptomatic females aged 30–49 years.27 BML 
were also associated with dietary fatty acid intake in 297 
middle-aged adults without clinical knee OA.51 Systemic 
factors, including metainflammation and dietary intake, 
might affect subchondral bone integrity, increasing sus-
ceptibility to damage from increased loading in obesity. 
However, some BML do regress; regression is thought 
to occur more frequently before the onset of clinical 
OA but to nevertheless also occur in OA.52 These data 
suggest that a variety of interactions between different 
risk factors contribute to the risk of knee OA posed by 
obesity. Understanding these interrelationships better 
will aid OA prevention.
Obesity and OA are independently associated with 
reduced physical activity,53,54 which has a further impact 
on body composition, increasing fat mass and reduc-
ing muscle mass.55 Thus, the combination of increased 
























Figure 1 | Mechanisms relating obesity to OA. With increasing obesity, joint 
loading, as well as fat mass, become greater. Higher levels of adiposity are 
accompanied by metainflammation, with production of adipokines and 
proinflammatory cytokines. The combined effect of adipocytokines and increased 
loading can facilitate the pathogenesis of OA, affecting bone, cartilage and 
synovial tissue. Abbreviation: OA, osteoarthritis.
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expression related to metainflammation may, in turn, 
contribute to reductions in physical activity and energy 
expenditure, thereby increasing obesity and creating a 
vicious cycle (Figure 2).
Weight management in OA 
Weight-loss requirement to reduce OA risk 
For the prevention of symptomatic knee OA, weight loss 
of approximately 5 kg in a woman of average height—the 
equivalent of a decrease of 2 BMI units—over a decade 
was enough to halve the risk of symptomatic and radio-
graphic knee OA, in women in the Framingham knee 
OA study.56 Christensen et al.,57 in a meta-analysis of 
randomized controlled trials (RCTs) of weight loss and 
symptomatic OA, showed that a mean 6.1kg weight loss 
was associated with significant reduction in pain, with 
 effect size of 0.2 (P = 0.05). Mean weight loss of 6.1 kg 
resulted in a reduction in self-reported disability, with 
the authors suggesting that weight loss of 10% would 
be expected to have a moderate-to-high clinical effect, 
according to self-reported disability.57
Besides the magnitude of weight loss, the rate of loss 
might also be important in achieving a positive outcome 
in terms of reduced OA risk. In many overweight people, 
weight loss of 0.25–0.60% per week is achievable and 
results in at least a moderate clinical effect with regard 
to pain and function, according to the above-mentioned 
meta-analysis of RCTs.57
Though the effect of weight loss on knee structure 
is less well studied than that on functional outcomes, 
existing data suggest a beneficial effect. Data from case–
control and cohort studies of the role of weight loss in the 
prevention of knee OA and structural change are scarce, 
because few participants lose weight.26,27 In 59 morbidly 
obese individuals with knee pain with or without early-
stage OA (Kellgren–Lawrence grade 0–1), weight loss 
after weight-loss surgery of 6 BMI units over 3 months 
improved joint-space width, potentially retarding the 
progression of structural change.58 The improvement 
in joint-space width might not reflect change in the 
amount of cartilage present,59 and might instead relate 
to positioning or meniscal extrusion.60 In another obese 
population (n = 111), 32% of whom had knee OA, weight 
loss seemed to slow structural progression over 2 years: 
weight loss >9.3 kg was associated with reduced cartilage 
thickness loss, and improvements in cartilage quality, as 
measured by glycosaminoglycan content assessed by 
delayed gadolinium-enhanced MRI of cartilage.61
Effects of weight loss in OA 
Weight loss results in a reduction in both fat and abso-
lute muscle mass.62,63 The Physical Activity, Inflammation 
and Body Composition Trial, showed that mean weight 
loss of 8.7% in older adults with knee pain was associ-
ated with improvements in all measures of function.64,65 
However, only improvements in the 6-minute walk 
test, and not in the Western Ontario and McMaster 
Universities arthritis index (WOMAC) function score 
or stair-climbing time,64,65 were specifically associated 
with increased fat loss rather than overall weight loss. 
Nevertheless, increases in fat loss were associated with 
greater improvements in muscle strength and quality,65 
suggesting that fat loss was beneficial. 
In contrast to the loss of fat, the loss of muscle mass is 
of concern, especially in an elderly population, as it may 
accelerate functional decline and loss of muscle strength, 
facilitating OA progression. The effect of weight loss, 
achieved by meal replacement, on muscle strength and 
power was assessed; although it was associated with loss 
of leg muscle tissue and strength, normalised muscle 
strength—that is, force generated per kilogram of muscle 
mass—was improved, as were symptoms.63 These data 
suggest that weight loss has a beneficial effect on muscle 
strength (relative to body size) and function, despite loss 
of lean tissue. 
Weight-loss interventions 
The cornerstone of obesity management has tradition-
ally been behavioural interventions addressing diet or 
physical activity, or both.66 However, overweight indi-
viduals must continually and consciously battle against 
the strong biological and environmental influences 
that promote weight gain. Treating obesity is difficult, 
requiring a constant negative energy balance that is enor-
mously difficult for many people to sustain, but effective 
weight loss has been demonstrated in obese people with 
knee pain67,68 and OA.57,62,69,70
Diet, physical activity and behaviour 
Restriction of dietary intake predictably results in weight 
loss,71 but manipulation of the contribution of macro-













Figu 2 | Obesity and OA: a vicious cycle. Obesity can 
affect th  pathogen sis of OA through bio echanical 
effects as well as via increased metainflammation. 
Increased obesity is associated with higher levels of joint 
loading and reduced levels of physical activity, which in turn 
reduces muscle strength. Combined, these effects can 
result in the structural changes of OA. Structural disease 
results in pain, which presents a barrier to physical activity, 
further reducing energy expenditure and resulting in 
reduced muscle mass and increased fat mass. Thus, 
thes  factor  may contribute to a vicious ycle of obesity 
and OA. Abbreviation: OA, osteoarthritis.
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In	 the	 1920s,	 a	 Swedish	 physician	 named	 Kylin	 first	 described	 the	 relationship	 between	
hypertension,	 hyperglycaemia	 and	 hyperuricaemia	 (137).	 Since	 then,	 the	 concept	 of	
clustering	the	metabolic	abnormalities	that	arise	from	increasing	prevalence	of	obesity	was	
becoming	 more	 recognised.	 This	 was	 further	 acknowledged	 in	 the	 1940s	 by	 Vague	 who	
associated	excess	upper	body	fat	deposits	with	this	model	(138).	Insulin	resistance	was	then	
linked	 to	 this	 condition	 around	 the	 end	 of	 1980s	 (139).	 Having	 received	much	 attention,	
various	terms	have	been	used	to	describe	this	theory	including	the	‘deadly	quartet’,	‘insulin	
resistance	syndrome’	and	‘syndrome	X’.	From	the	mid-1990s	until	now,	it	is	widely	known	as	






over	 the	 globe	 and	 is	 realised	 as	 the	 new	 epidemic	 of	 the	 21st	 century.	 According	 to	
International	Diabetes	Federation	(IDF),	 it	 is	estimated	that	a	quarter	of	 the	world’s	adults	
are	affected	by	MetS	(16).	A	systematic	review	looking	at	the	Asia-Pacific	territories,	where	
greater	 than	 50%	 of	 the	 world’s	 population	 resides,	 the	 prevalence	 of	MetS	 varied	 from	
11.9%	 in	 Philippines	 to	 49%	 in	 urban	 Pakistan.	 Females	 and	 urban	 residents	 were	






between	 59	 and	 70	 years	 and	 above	 70	 years	 had	 an	 increased	 prevalence	 of	 43.5%	 and	
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Numerous	expert	groups	have	 tried	developing	an	 internationally	accepted	and	 integrated	
definition	 of	 the	 MetS	 namely	 the	 WHO,	 the	 European	 Group	 for	 the	 Study	 of	 Insulin	
Resistance	 (EGIR),	 The	 National	 Cholesterol	 Education	 Program	 Expert	 Panel	 on	 the	
Detection,	 Evaluation	 and	 Treatment	 of	 High	 Blood	 Cholesterol	 in	 Adults	 –	 Third	 Adult	
Treatment	Panel	 (NCEP-ATP	 III),	 the	American	Association	of	Clinical	Endocrinology	 (AACE)	
and	 the	 IDF	 (147).	 Although	 the	 groups	 agreed	 over	 the	 core	 components	 i.e.	 obesity,	




IDF	MetS	world-wide	definition	 is	 summarised	 in	Table	4.	To	be	diagnosed	with	MetS,	 the	
individual	 needs	 to	 acquire	 central	 obesity	 combined	 with	 whichever	 two	 of	 the	 four	
supplementary	components.	It	is	assumed	that	if	the	subject	has	a	BMI	of	more	than	30,	the	
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waist	 circumference	 is	 expected	 to	 be	 substantial	 and	meet	 the	major	 criterion	 (149).	 By	





















Central	 obesity	 according	 to	
ethnicity	 (waist	 circumference	 –	
cm)	
	 Males Females 
Europeans	 ≥ 94	 ≥ 80	
USA	(Caucasians)	 ≥ 102	 ≥ 88	
South	Asians	 ≥ 90	 ≥ 80	
Chinese	 ≥ 90	 ≥ 80	






















of	 OA	 (150).	 Oxidised	 LDL	 is	 able	 to	 stimulate	 synovial	 cells	 including	 synovial	 fibroblast,	
macrophages	 and	 endothelial	 cells.	 As	 a	 result,	 this	 prompts	 release	 of	 pro-inflammatory	
cytokines,	growth	factors	together	with	MMPs	(150).	Hyperlipidaemia-induced	lipid	build	up	
in	joint	tissues	particularly	in	chondrocytes	can	also	initiate	OA	progression	(151).	Tsezou	et	
al	 reported	 that	 genes	 responsible	 for	 controlling	 cholesterol	 efflux	 were	 found	 to	 be	
reduced	 in	 osteoarthritic	 cartilage.	 Moreover,	 intracellular	 lipid	 deposits	 were	 also	
discovered	to	be	present	in	osteoarthritic	chondrocytes	(152).	
	
A	 number	 of	 pathogenic	 in-vitro,	 ex-vivo	 and	 in-vivo	 effects	 of	 hyperglycaemia	 on	 joint	
tissues	and	cells	have	been	reported	(153).	Indeed,	high	blood	glucose	encourages	the	local	
development	 of	 oxidative	 stress	 and	 Advanced	 Glycation	 End	 products	 (AGEs)	 in	 joint	
tissues.	These	lead	to	altered	mechanical	characteristics	of	the	extracellular	matrix,	reduce	
the	production	of	proteoglycan	and	 increase	 the	collagen	stiffness	 (153).	Apart	 from	that,	
chondrocytes	are	capable	to	generate	AGEs	receptor	and	once	they	are	excited	by	ligands,	
they	can	 induce	pro-inflammatory	protein	molecules	mainly	 IL-6	and	TNF-α	(154).	Another	






Alas,	 less	 attention	 was	 given	 to	 associate	 hypertension	 with	 OA.	 Some	 researchers	
proposed	 that	 subchondral	 ischaemia	 can	 happen	 followed	 by	 impairment	 of	 nutrient	
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syndrome.	 When	 considering	 the	 pathobiology	 of	 these	 conditions,	 the	 main	 distinctive	
feature	is	the	destruction	of	collagen	whereby	they	share	common	biomarkers.		
	






Adipose	 tissue	was	once	believed	 to	be	an	 inactive	energy	 storing	 vestibule	but	 since	 the	
discovery	 of	 the	 hormone	 leptin	 from	 white	 adipose	 tissue	 in	 1994,	 there	 has	 been	 a	
significant	 shift	of	understanding	of	what	 this	 tissue	can	produce	 (157).	 It	has	been	 found	
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that	adipose	tissue	produces	proteins	called	adipokines	that	exert	multiple	functions	which	
involved	 not	 only	 in	 glucose	 and	 lipid	 metabolism,	 but	 also	 regulation	 of	 immune	 and	




In	 2003,	 Helene	 Dumond	 et	 al	 discovered	 the	 initial	 role	 of	 leptin	 and	 this	 initiated	 the	
expedition	 to	 scrutinise	 adipokines	 further	 as	 a	 metabolic	 connection	 between	 OA	 and	
obesity	(21).	Dysregulation	of	adipose	tissue-derived	inflammatory	molecules	including	IL-1,	




Sex	 dimorphism	 in	 human	 particularly	 our	 body	 constituent	 is	 well	 documented	 in	 the	
literature.	 It	has	been	verified	 that	 fat	 composition	 is	different	between	men	and	women	
(159).	 For	 any	 specified	 class	 of	 BMI,	 females	 do	 possess	 a	 bigger	 share	 of	 fat	 content	





Leptin	 is	 a	 16	 kDa	 polypeptide	 which	 consists	 of	 167	 amino	 acids	 (157).	 Its	 cytogenetic	
location	in	humans	is	at	chromosome	7q32.1	(161).	It	is	transcribed	from	the	OB	gene	with	a	
DNA	of	more	than	15000	base-pairs.	It	comprises	of	3	exons	and	separated	by	2	introns	that	
spans	for	approximately	18	kb.	 It	 is	primarily	generated	by	WAT	and	to	a	 lesser	degree	by	
BAT.	It	circulates	in	the	body	freely	or	bounded	to	binding	proteins	(161,	162).	The	normal	
plasma	 level	 for	 leptin	 in	 healthy	 adults	 is	 14.2+/-	 2.2ng/ml	 (males	 9.5	 +/-	 1.1	 ng/ml	 and	
females	19.8+/-	2.5ng/ml)	(163).	Leptin	works	via	the	leptin	receptor	(LEPR)	which	is	made	
up	of	a	single-transmembrane	domain	receptor	of	the	cytokine	receptor	family.	It	belongs	to	
a	 class	 I	 cytokine	 receptor	 similar	 to	 those	 for	 interferon	 and	 growth	 hormone	 (164).	 Its	
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specific	 receptors	 in	 the	 hypothalamus	 that	 are	 responsible	 in	 regulating	 the	
neuroendocrine	 function	 (162).	 Moreover,	 it	 also	 involves	 in	 regulating	 haematopoiesis,	
angiogenesis,	wound	healing,	immune	response	and	inflammatory	action	(161).	Leptin	was	
also	 documented	 as	 an	 adipokine	 that	 can	 be	 utilised	 to	 help	 prevent	 obesity	 as	 its	
deficiency	was	identified	in	obese	ob/ob	mice	(165).	However,	humans	do	very	infrequently	




it	 is	 recognised	 to	 encourage	 the	 production	 of	 IL-1b,	 increase	 the	 influence	 of	 pro-
inflammatory	 cytokines	 and	 generate	 the	 MMPs	 expression	 in	 the	 OA	 cartilage.	 This	







It	 is	 also	 noted	 that	 leptin	 has	 important	 anabolic	 effect	 on	 bone	 health.	 Liang	 et	 al	
identified	a	novel	evidence	 that	 indicates	 the	 stimulatory	activity	on	chondrocytes	via	 the	





Individuals	who	have	high	BMI	also	exhibit	higher	 leptin	 levels	compared	to	 lean	subjects.	
On	average,	a	gram	of	adipose	tissue	produces	leptin	twice	greater	in	obese	than	non-obese	







Apelin	 was	 originally	 discovered	 as	 a	 new	 team	 player	 in	 the	 fat-tissue	 derived	 cytokine	
group	by	Tatemoto	et	al.	It	was	isolated	as	an	endogenous	ligand	for	the	APJ	receptor	(175,	
176).	 Its	 gene	 has	 been	mapped	 to	 chromosome	Xq26.1	 producing	 a	 pre-propeptide	 that	
comprises	of	77	amino	acids.	The	most	abundant	form	is	apelin-36	and	it	can	be	divided	into	
several	 more	 potent	 molecular	 structures	 including	 apelin-12,	 -13	 and	 -17	 but	 they	 are	




as	 a	 cellular	 transmembrane	 receptor	 in	 1993.	 It	 exhibits	 a	 sequence	 similarity	 to	 the	
receptor	for	type	1	angiotensin	II	whereby	it	also	known	as	AGTRL1	(178).	It	was	labelled	an	
orphan	GPCR	as	 it	was	not	activated	by	angiotensin	 II	until	apelin	was	discovered	 in	1998	
(179).		
	
The	 apelin-APJ	 conjugate	 is	 heterogeneously	 dispersed	 everywhere	 in	 the	 human	 body	
especially	 in	 adipose,	 heart,	 brain,	 liver	 and	 lung	 tissues	 (180).	 Its	 signalling	 route	 plays	 a	
significant	part	 in	the	creation	of	functional	vascular	system	in	adipose	tissue	(181).	 It	was	
also	found	that	apelin	showed	a	cardio-protective	role	against	ischaemia	reperfusion	injury	
and	 initiated	 the	 vasodilatation	 of	 the	 nitric	 oxide-dependent	 arteries	 (23).	 In	 the	 central	
nervous	 system,	 abundant	 apelin-36	 is	 identified	 in	 murine	 models	 specifically	 in	 the	
paraventricular	 nucleus	 and	 the	 hypothalamic	 supraoptic	 nucleus.	 These	 are	 neuronal	
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bodies	 that	 extend	 into	 the	 pituitary	 gland	 secreting	 hormones	 that	 regulates	 the	 body’s	
fluid	homeostasis	(182).	
	
Apelin	 also	 acts	 as	 an	 anti-inflammatory	 adipocyte-derived	 factor	 that	 diminishes	
macrophage	burden	and	inhibits	its	accumulation	in	the	arterial	wall,	showing	a	direct	effect	
in	 preventing	 vascular	 inflammation.	 Furthermore,	 it	 appears	 to	 have	 an	 anti-aneurysmal	
ability	 in	addition	to	its	anti-atherogenic	salutary	effect.	 It	 is	found	to	downregulate	TNF-α	
and	Monocyte	Chemoattractant	Protein	(MCP)-1	expression	in	cultured	cells	(24).		
	
Since	 apelin	 is	 considered	 as	 a	 novel	 adipokine	 with	 little	 knowledge	 of	 its	
pathophysiological	implications,	it	has	been	suggested	that	apelin	has	a	positive	relationship	
with	obesity	and	those	who	are	diagnosed	with	type	one	diabetes	(183).	When	considering	
feeding	behaviour	 in	murine	models,	a	decrease	 in	concentration	of	plasma	 insulin	by	5.4	







185,	 186).	 They	 described	 that	 apelin	 could	 stimulate	 osteoblast	 proliferation	 via	 the	
APJ/PI3k/Akt	pathway	and	at	the	same	time,	safeguard	osteoblasts	against	apoptosis	 (25).	
These	 results	 seem	 to	 imply	 that	 apelin	 participates	 in	 bone	 metabolism	 leading	 to	
formation	of	osteophytes.		
	
On	 the	 other	 hand,	 another	 study	 reported	 that	 apelin	 has	 an	 effect	 on	 the	 articular	
cartilage	via	a	catabolic	process.	In	vitro	study,	apelin	triggered	a	substantial	increase	in	the	
mRNA	of	IL-1ß	and	MMP-1,	-3,	-9.	In	the	same	manner,	in	vivo	study	also	reported	a	rise	in	
the	 expression	 of	 these	 cytokines	 including	 a	 reduced	 level	 of	 collagen	 type	 II	 when	 this	
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In	 the	 beginning,	 PGRN	was	 discovered	 from	 a	 conditional	 tissue	 culture	medium	 and	 is	
classified	as	an	autocrine	growth	 factor	consisting	of	593-amino	acid	 (188,	189).	 It	 is	a	88	
kDa	 secreted	 glycoprotein	 and	 is	 heavily	 glycosylated	 (190).	 Its	 gene	 is	 located	 at	
chromosome	 17q21.31	 which	 comprises	 of	 13	 exons	 covering	 approximately	 3700	 base-
pairs	 including	 a	 noncoding	 exon	 0	 (190).	 PGRN	 can	 be	 cleaved	 further	 into	 smaller	 but	
mature	granulins	with	sizes	of	around	6kDa	peptides	(191).	The	normal	serum	progranulin	
level	 in	 healthy	 adults	 is	 79.34+/-47.12	 ng/ml	 (males	 75.81+/-45.75	 ng/ml	 and	 females	
73.59+/-42.28	ng/ml)	(192).	
	
PGRN	 is	 produced	 by	 a	 broad	 range	 of	 tissues	 including	 human	 articular	 cartilage	 and	
adipose	 tissue	 (193,	 194).	 It	 is	 involved	 in	multiple	 pathophysiological	 activities	 including	
inflammation,	bone	regeneration,	tumorigenesis	as	well	as	wound	healing	(195-198).	Since	
the	 discovery	 of	 mutation	 in	 PGRN	 causing	 frontotemporal	 dementia,	 this	 led	 to	 further	
studies	 implicating	 its	 protective	 characteristics	 in	 other	 diseases	 that	 involve	 the	 human	
brain	including	Parkinson’s,	Alzheimer’s	and	Creutzfeldt-Jakob	diseases	(27,	28).	
	
PGRN	 shows	 evidence	 of	 convincing	 anti-inflammatory	 activity	 in	 a	 number	 of	 illnesses	
which	include	dermatitis,	plaque-like	psoriasis,	 lung	inflammation	and	inflammatory	bowel	
disease	(29-32).	Its	most	distinct	function	can	be	referenced	to	its	central	inhibition	on	TNF-
α	 via	 its	 interaction	 with	 Tumour	 Necrosis	 Factor	 Receptor	 (TNFR)1	 and	 TNFR2	 (199).	
Another	 pathway	 involved	 showing	 beneficial	 effect	 of	 PGRN	 is	 the	 Wnt/beta-catenin	




However,	 PGRN	 demonstrates	 detrimental	 role	 in	 regulating	 glucose	 and	 energy	
metabolism.	 In	 murine	 model,	 diet-induced	 obesity	 mice	 with	 PGRN	 deficiency	 showed	
lower	body	weight	and	improved	insulin	sensitivity	whereas	administration	of	recombinant	
PGRN	 gave	 rise	 to	 impaired	 glucose	 tolerance	 and	 insulin	 resistance	 (194).	 Furthermore,	
circulating	serum	PGRN	levels	were	considerably	greater	in	patients	with	type	2	diabetes.	It	
was	 also	 associated	 with	 visceral	 obesity	 and	 dyslipidaemia.	 The	 changes	 observed	 were	




in	 the	 cartilage	of	OA	and	 rheumatoid	 arthritis	 (RA)	 individuals	 (193).	 Coinciding	 research	
also	reported	that	PGRN	genes	were	isolated	in	an	effort	to	study	OA-associated	molecules	
(33).	Conceivable	evidence	reported	that	this	adipokine	was	capable	of	antagonising	TNF-α	
by	 binding	 with	 its	 receptors	 thus,	 serving	 as	 an	 anti-inflammatory	 function	 in	 studies	
involving	mice	diagnosed	with	inflammatory	arthritis	(202-204).	Zhao	et	al.	experimented	on	
culture	 assay	 for	 human	 cartilage	 and	 they	 found	 that	 there	 was	 a	 marked	 decrease	 in	
proteoglycan	 damage	 when	 PGRN	 was	 introduced.	 They	 also	 identified	 a	 significant	
decrease	 in	 the	 production	 of	 catabolic	 inflammatory	 molecules	 such	 as	 MMP-13,	 A	
Disintegrin	 and	 Metalloproteinase	 with	 Thrombospondin	 motifs	 (ADAMTS)-5,	




antagonist	 for	TNF-α	 signalling	by	 selectively	 interacting	with	TNFR1	and	TNFR2	pathways	
(34).	 It	 has	 been	 investigated	 in	 mice	 with	 rheumatoid	 arthritis	 and	 dermatitis	 which	
demonstrated	 competitive	 inhibition	 of	 TNF-α	 (30,	 203).	 This	 provides	 a	 potential	
















The	 increasing	 requirement	 for	 evidence-based	 practice	 demands	 the	 employment	 of	
reliable	and	validated	instruments	as	assessment	tools.	This	will	equip	clinicians/researchers	
with	 factual	 and	 quantified	 health	 status	 data.	 Self-report	 instruments,	 as	 opposed	 to	




Western	 Ontario	 and	 McMaster	 Universities	 Osteoarthritis	 (WOMAC)	 index	 is	 an	
internationally	 recognised	and	commonly	utilised	patient	 reported	outcome	measure	 that	
evaluates	 symptoms	 over	 the	 preceding	 48	 hours.	 It	 is	 an	 OA-specific,	 patient-oriented	

























concept	and	 is	 scored	 from	0-100	where	bigger	scores	are	 interpreted	as	greater	health.	

















SF-12	 is	 a	 rapid	and	practical	 assessment	on	patient’s	physical	 and	mental	wellbeing	with	
commendable	validity	and	reliability	(218,	219).	It	appears	to	be	useful	 in	large	population	
health	 surveys	 and	 it	 can	 also	 be	 utilised	 in	 combination	 with	 disease-specific	
questionnaires.	 A	 cross-sectional	 study	 comprising	 of	 numerous	 number	 of	 participants	
advocated	the	use	of	SF-12	rather	than	SF-36	owing	to	the	fact	that	a	greater	proportion	of	
the	questionnaires	were	being	filled	up	and	the	lack	of	floor	effects	(213).	In	the	preceding	
research,	 it	 has	 shown	 that	 patients	 took	 more	 time	 (an	 average	 of	 10-15	 minutes)	 to	





















ELISA	 system	 operates	 using	 the	 principle	 of	 specific	 antigen-antibody	 recognition	
interactions.	 This	 allows	 an	 effective	 antibody	 quantitation	 or	 antigen	 concentration	 in	 a	
variety	of	samples	 including	blood,	serum,	plasma	or	supernatant.	A	wide	variety	of	ELISAs	





7).	 The	 substance	 to	be	 analysed	must	possess	 at	 least	 two	antigen-binding	 sites	 to	 allow	
antibody	 attachment.	 In	 broad	 terms,	 monoclonal	 and	 polyclonal	 antibodies	 are	 used	 as	
detection	and	capture	antibodies	respectively.	The	monoclonal	antibody	operates	by	binding	
to	 the	 same	epitope	present	 on	 the	 target	 antigen	 thus	 leading	 to	 an	 extremely	 sensitive	












of	 initial	 incubation.	As	 soon	as	 the	 remaining	detection	antibody	 is	washed	and	disposed	
off,	an	enzyme	labelled	antibody	is	subsequently	mixed	into	the	wells	so	it	can	bind	onto	the	
detection	 antibody	 to	 achieve	 the	 four-member	 sandwich.	 After	 the	 wells	 have	 been	
incubated	 further	and	 the	unbound	enzyme	has	been	cleared,	a	 substrate	solution	 is	 then	
added.	This	will	react	with	the	bound	enzyme	and	generate	a	colour	change.	The	amount	of	






antibody,	 an	 established	 complementary	 antigen	 or	 antibody	 needs	 to	 be	 produced	 first	
which	 can	 be	 very	 difficult	 to	 find.	 Secondly,	 non-specific	 attachment	 of	 the	 antigen	 or	
antibody	to	the	well-plate	can	generate	a	high-positive	result	leading	to	inaccurate	outcome.	
Furthermore,	 the	 enzyme-mediated	 change	 in	 colour	 will	 continue	 to	 react	 and,	 if	 left	
behind	 for	 a	prolonged	duration	of	 time,	 the	 colour	 intensity	will	 change	and	 cause	 false-
positive	 result	 (226).	 Majority	 of	 the	 time,	 the	 results	 obtained	 usually	 display	 a	 dose-
response	 curve	 that	 match	 the	 standard	 curve	 following	 the	 kit’s	 recommendation.	
Sometimes,	the	samples	may	fall	outside	the	dynamic	detectable	range	of	the	assay	due	to	












Recent	 studies	 demonstrated	 that	 many	 heterogeneous	 adipokines	 are	 related	 to	 clinical	
parameters	of	disease	activity	in	the	knee	joint	and	portray	a	crucial	part	in	the	development	
of	 metabolic-associated	 OA	 (227-230).	 Hence,	 we	 hypothesised	 that	 there	 would	 be	 a	
difference	 in	plasma	 leptin,	 apelin	 and	progranulin	 concentration	with	 increasing	BMI	 and	






syndrome	 will,	 hopefully,	 provide	 insight	 into	 the	 role	 of	 adipokines	 contributing	 to	 the	
pathogenesis	of	 knee	OA.	This	 could	 result	 in	breaking	new	grounds	on	curative	 focus	on	














At	 the	 same	 time,	we	can	determine	how	 these	 two	molecules	 react	with	 increasing	BMI	
levels	 and	 across	 gender.	 Therefore,	 by	 understanding	 the	 mechanisms	 involved	 and	 its	
interactions	 with	 leptin,	 we	 could	 bridge	 and	 address	 our	 knowledge	 gap	 in	 this	matter.	
Recently,	 PGRN	 has	 established	 a	 successful	 achievement	 demonstrating	 its	 potent	 anti-








The	 association	 between	 obesity	 and	 knee	 OA	 has	 been	 proven	 to	 be	 significant	 when	







Many	 cytokines/adipokines	 and	 chemokines	 exist	 in	 very	 small	 amount	 in	 the	 peripheral	








Plasma	samples	were	chosen	because	of	 several	 reasons.	Firstly,	 leptin	 receptor	has	been	
detected	 in	 human	 platelets.	 Therefore,	 by	 letting	 the	 samples	 coagulate	 i.e.	 obtaining	
serum	 specimens,	 it	 will	 presumably	 underestimate	 the	 detected	 leptin	 concentrations	
(236).	Secondly,	plasma	samples	have	been	verified	to	show	a	better	recovery	of	cytokines	
when	 compared	 to	 its	 serum	 counterparts	 (237).	 Lastly,	 it	 is	 found	 that	multiple	 studies	










This	 can	 be	 achieved	 by	 detecting	 the	 adipokines	 in	 the	 plasma	 of	 the	 individuals	 using	

















University	Hospital	NHS	Trust	by	which	they	have	met	the	 inclusion	criteria	 for	 this	study.	
Recruitment	 occurred	between	 September	 2008	 and	 February	 2017	whereby	 participants	
were	given	the	opportunity	to	ask	questions	with	the	member	of	research	team	regarding	




OA	 of	 the	 knee	 joint	 and	 planned	 for	 primary	 knee	 arthroplasty.	 They	 were	 capable	 of	
offering	 informed	 consent	 (see	 appendix	 E)	 and	 willing	 to	 participate	 in	 the	 study.	 The	
exclusion	 criteria	 included	 individuals	 who	 were	 diagnosed	 with	 OA	 other	 than	 primary	
aetiology,	 had	 a	 past	 history	 of	 liver	 or	 kidney	 failure	 or	 on	 dialysis,	 showed	 evidence	 of	




The	 study	has	 been	 approved	 to	 proceed	by	 the	Research	 Ethics	 Committee	 (REC)	 at	 the	
University	of	 Liverpool	 (see	appendix	K).	 It	was	handled	according	 to	 the	proposition	 that	















The	 research	 team	 has	 recruited	 participants	 who	 presented	 to	 the	 outpatient	
trauma/orthopaedic	 clinic	with	 knee	 joint	 pain.	 Those	 eligible	 to	 be	 recruited	were	 given	
information	about	the	study	and	invited	to	discuss	 it	 further.	Anyone	willing	to	participate	




The	 research	 team	would	have	 recorded	 the	 reason/s	 for	any	withdrawal	and	 the	 subject	







general	 health,	 past	 medical	 history	 (including	 history	 of	 OA	 in	 other	 joints),	 regular	
	 49	











The	 arterial	 blood	 pressure	 reading	 was	 acquired	 whilst	 the	 patient	 was	 seated	 using	 a	
medical	 automated	 manometer.	 Recording	 for	 both	 systolic	 as	 well	 as	 diastolic	 blood	
pressure	were	obtained.	The	procedure	was	performed	twice	and	its	average	was	calculated	
and	 recorded.	 Hypertension	 is	 classified	 in	 accordance	 to	 the	 IDF	 definition	 with	 systolic	
Blood	 Pressure	 (BP)	 ≥ 130mmHg	 and	 diastolic	 BP	 ≥ 85mmHg	 (149).	 Alternatively,	 those	






proceed	 to	 the	 Radiology	 Department	 of	 the	 Royal	 Liverpool	 and	 Broadgreen	 University	
Hospitals	 to	 have	 their	 knees	 x	 rayed.	 A	 standing,	 weight	 bearing,	 antero-posterior	 (AP)	




















During	 outpatient	 visit,	 21	 mls	 of	 fasting	 venous	 blood	 sample	 were	 obtained	 by	 the	
research	 team.	 The	 blood	 samples	 were	 collected	 as	 per	 Standard	 Operating	 Procedures	
(SOPs)	and	sample	handling	procedure.	Three	millilitres	of	blood	was	placed	 in	a	 light	grey	
top	vacutainer	for	fasting	glucose	 level	and	5mls	of	blood	in	a	gold	top	vacutainer	for	 lipid	
profile.	 The	 remaining	 7.5	 mls	 serum	 and	 5.5	 mls	 lithium	 heparin	 plasma	 of	 the	 blood	
samples	were	placed	in	sterile	vacutainers	which	were	anonymized-linked	to	the	identifiable	
patient	 information	by	a	unique	study	number.	Patients’	 identifiers	were	removed	prior	to	
transport	 to	 the	 storage	 facilities	 in	 the	 laboratories	 of	 the	 University	 of	 Liverpool.	 After	
collection,	 the	 samples	 were	 processed	 and	 stored	 for	 future	 use	 in	 the	 Liverpool	






LMB	 is	 a	 Human	 Tissue	 Authority	 (HTA)	 approved	 research	 biobank	 under	 the	 ethical	
approval	 of	 the	 central	 Liverpool	 ethics	 committee	 (reference	 15/NW/0661).	 The	 LMB	
sponsor	 is	 the	 University	 of	 Liverpool	 (reference	 UOL001150)	 and	 operates	 under	 HTA	
license	 (reference	 12020).	 The	 LMB	 staff	 members	 are	 also	 involved	 in	 consenting	
participants,	 collection	 of	 tissue	 and	 data,	 samples	 logging,	 sample	 tracking,	 storage	 and	





Samples	were	 link-anonymised	 and	 blinded	 using	 participants	 unique	 study	 number	 by	 a	
member	 of	 the	 LMB.	 The	 assessor	 of	 the	 laboratory	 samples	 was	 not	 able	 to	 identify	
participants,	thus	reducing	assessor	bias.	
	
The	blood	samples	were	centrifuged	at	1000g	 for	15	minutes	by	 the	LMB	staff	 in	order	 to	







using	 commercially	 available	 ELISA	 kits	 and	 they	 were	 used	 once	 enough	 samples	 were	
obtained	to	fill	in	all	the	well-plates	so	that	the	test	could	be	carried	out	altogether.	
	
Plasma	 leptin	 concentration	 was	 performed	 using	 Quantikine	 ELISA	 Human	 Leptin	
Immunoassay,	R&D	Systems,	Minneapolis,	MN	with	a	reported	precision	of	3.0	–	3.3%	(intra-
assay)	and	3.5	–	5.4%	(inter-assay).	The	Minimum	Detectable	Dose	 (MDD)	of	 this	kit	 is	7.8	
pg/ml	and	 its	test	range	 is	15.6	pg/ml	–	1000	pg/ml.	For	further	methodology	protocol	 for	
this	ELISA,	please	see	Appendix	H.	
	
Plasma	 apelin	 concentration	 was	 analysed	 using	 Human	 Apelin	 ELISA	 Kit,	 Abbexa	 ltd,	





Yangpu	 Dist,	 Shanghai	 with	 a	 reported	 precision	 of	 <	 8%	 (intra-assay)	 and	 <	 10%	 (inter-











+/-	 standard	 deviations,	 whereas	 non-normally	 distributed	 continuous	 variables	 were	
presented	as	median	(range).		
	
For	 parametric	 and	 normally	 distributed	 data,	 two-way	 Multivariate	 Analysis	 of	 Variance	
(MANOVA)	were	used	while	for	those	that	were	non-normally	distributed,	Mann-Whitney	U	
test	or	Kruskal-Wallis	test	were	employed.	With	regards	to	post	hoc	tests,	parametric	data	







Pearson	 correlation	 coefficient	 was	 used	 to	 detect	 associations	 between	 parametric	
















16.5	à	 17.	 This	 sample	 can	 be	 divided	 equally	 to	 six	 groups,	where	 each	 group	 contains	












In	our	 study,	we	managed	 to	 recruit	 subjects	 as	planned	 in	 the	methodology	 section	4.2.	
Therefore,	 19	male	 participants	 and	 19	 female	 participants	were	 enrolled	 in	 each	 group,	
leading	to	a	total	of	114	subjects	for	the	whole	three	groups.		
	 	
The	 data	were	 analysed	 using	 SPSS	 and	 they	 have	 been	 proven	 to	 be	 non	 parametric	 in	
nature	as	assessed	using	Shapiro	Wilk’s	test	(p	<	0.05).	Therefore,	all	of	the	statistical	tests	




















for	multiple	 comparisons.	Values	are	derived	 from	mean	 ranks	unless	 specified	otherwise	
and	 adjusted	 p-values	 were	 reviewed.	 The	 post	 hoc	 analysis	 revealed	 a	 statistically	
significant	 difference	 between	 non	 obese	 (75.86)	 and	 obese	 group	 (38.29)	 (p	 <	 0.001).	






















for	multiple	 comparisons.	Values	are	derived	 from	mean	 ranks	unless	 specified	otherwise	
and	 adjusted	 p-values	 were	 reviewed.	 The	 post	 hoc	 analysis	 revealed	 a	 statistically	
significant	 difference	 between	 non	 obese	 (19.50)	 and	 obese	 group	 (74.68)	 (p	 <	 0.001).	
Statistically	 significant	 difference	 was	 also	 seen	 between	 non	 obese	 (19.50)	 and	 MetS	




































for	multiple	 comparisons.	Values	are	derived	 from	mean	 ranks	unless	 specified	otherwise	
and	 adjusted	 p-values	 were	 reviewed.	 The	 post	 hoc	 analysis	 revealed	 a	 statistically	
significant	 difference	 between	 non	 obese	 (68.01)	 and	 obese	 group	 (48.21)	 (p	 <	 0.01).	
However,	 no	 significant	 difference	 was	 found	 between	 obese	 (48.21)	 and	 MetS	 group	





































































had	similar	 findings,	a	difference	 in	proportions	of	 (0.596-0.474)	0.122.	Unfortunately,	 the	



















female	 patients	 (42.1%)	 had	 upper	 limb	 joint	 involved	 with	 OA	 whilst	 8	 male	 patients	
























A	 two-way	MANOVA	was	 performed	with	 two	 independent	 variables	 (group	 and	 gender)	
and	dependent	variables	(ranks	of	leptin,	apelin	and	PGRN	levels)	(Figures	15,	16	&	17).	
	
There	 was	 no	 linear	 relationship	 between	 the	 dependent	 variables,	 as	 assessed	 by	
scatterplot,	 and	 no	 evidence	 of	multicollinearity,	 as	 assessed	 by	 Pearson	 correlation	 (r	 <	
0.9).	There	were	three	univariate	outliers	in	the	data,	as	assessed	by	inspection	of	a	boxplot,	
but	no	multivariate	outlier	was	seen	in	the	data,	as	assessed	by	Mahalanobis	distance	(p	>	





The	 interaction	 effect	 between	 groups	 and	 gender	 on	 the	 combined	dependent	 variables	
was	not	statistically	significant,	F	(6,	212)	=	1.068,	p	=	0.383,	Wilks’	lambda	=	0.942,	partial	












was	 performed.	 Rank	of	 leptin	 for	 non	obese	 group	was	 49.96	 (95%	CI,	 -61.21	 to	 -38.72)	
lower	than	obese	group	and	this	was	statistically	significant,	p	<	0.001.	Rank	of	 leptin	for	
	 68	
non	obese	was	also	43.36	 (95%	CI,	 -54.60	 to	 -32.11)	 lower	 than	MetS	group	and	 this	was	
statistically	significant,	p	<	0.01.	Post	hoc	analysis	was	not	applied	to	gender	because	there	
was	 less	 than	3	categories	available.	Rank	of	 leptin	was	higher	 in	 females	with	a	mean	of	

























































Preliminary	 analyses	were	 performed	 to	 ensure	 no	major	 violation	of	 the	 assumptions	 of	
linearity	 and	 homoscedasticity.	 Following	 Cohen	 interpretations,	 r	 =	 0.1	 to	 0.29	 would	
suggest	 a	 small	 correlation;	 r	 =	0.30	 to	0.49	would	 suggest	medium	correlation	whilst	 r	 =	
	 72	













The	 relationship	 between	 leptin	 levels	 and	 age	 was	 investigated	 using	 Spearman’s	
correlation.	There	was	a	small	negative	correlation	between	the	two	variables,	rs	=	-0.222,	
n	=	114,	p	=	0.018.	Further	analyses	 looking	at	 the	 relationship	between	 leptin	 levels	and	















The	 relationship	 between	 leptin	 levels	 and	 BMI	 was	 investigated	 using	 Spearman’s	
correlation.	There	was	a	large	positive	correlation	between	the	two	variables,	rs	=	0.681,	n	=	
114,	p	<	0.001.	Further	analyses	looking	at	the	relationship	between	leptin	levels	and	each	
group’s	 BMI	 showed	 two	 statistically	 significant	 findings;	 a	 positive	 medium	 correlation	
between	leptin	levels	and	obese	group,	rs	=	0.350,	n	=	38,	p	=	0.031	and	a	positive	medium	
correlation	between	leptin	levels	and	MetS	group,	rs	=	0.418,	n	=	38,	p	=	0.009.	Looking	at	
gender’s	 BMI,	 a	 large	 positive	 correlation	 was	 detected	 between	 female	 BMI	 and	 leptin	

























and	non	obese	 group,	 rs	 =	 -0.369,	 n	 =	 38,	 p	 =	 0.022.	 Looking	 at	 gender’s	 PCS	 results	 and	














The	 relationship	 between	 leptin	 levels	 and	 SF12	 was	 investigated	 using	 Spearman’s	
correlation.	 There	 was	 a	medium	 negative	 correlation	 between	 the	 two	 variables,	 rs	 =	 -
0.350,	 n	 =	114,	 p	 <	0.001.	However,	 further	 analyses	 looking	 at	 the	 relationship	between	
leptin	 levels	 and	 each	 subgroup’s	 SF12	 results	 showed	 a	medium	 negative	 correlation	
between	SF12	and	non	obese	leptin	levels,	rs	=	-0.345,	n	=	38,	p	=	0.034.	Similarly,	a	medium	
negative	 correlation	 between	 SF12	 and	 MetS	 leptin	 levels,	 rs	 =	 -0.384,	 n	 =	 38,	 p	 =	
0.017Looking	at	gender’s	SF12	results	and	leptin	levels,	female	leptin	levels	had	a	medium	




















































































The	 relationship	 between	 leptin	 levels	 and	 Monocytes	 count	 was	 investigated	 using	
Spearman’s	correlation.	There	was	no	statistically	significant	correlation	seen	between	the	
two	parameters	in	general,	rs	=	-0.117,	n	=	114,	p	=	0.217.	However,	further	analyses	looking	
at	 the	 relationship	 between	 leptin	 levels	 and	 each	 subgroup	 showed	 a	medium	negative	
correlation	between	leptin	levels	and	MetS	group,	rs	=	-0.338,	n	=	38,	p	=	0.038.	There	was	















rs	=	0.289,	n	=	114,	p	<	0.002.	Further	analyses	 looking	at	 the	relationship	between	 leptin	
levels	 and	 each	 subgroup’s	 S100A8/A9	 results	 showed	 a	 medium	 positive	 correlation	
between	 S1008/A9	 and	 MetS	 leptin	 levels,	 rs	 =	 0.424,	 n	 =	 38,	 p	 =	 0.008.	 There	 was	 no	














The	 relationship	 between	 apelin	 levels	 and	 age	 was	 investigated	 using	 Spearman’s	
correlation.	There	was	no	statistically	significant	correlation	between	the	two	variables,	rs	=	
-0.085,	n	=	114,	p	=	0.371.	However,	 further	analyses	 looking	at	 the	relationship	between	
apelin	 levels	 and	 each	 subgroup’s	 age	 results	 showed	 a	 medium	 negative	 correlation	
between	 age	 and	 non	 obese	 apelin	 levels,	 rs	 =	 -0.358,	 n	 =	 38,	 p	 =	 0.027.	 There	 was	 no	














































The	 relationship	 between	 apelin	 levels	 and	 MCS	 for	 SF12	 results	 was	 investigated	 using	






correlation.	 On	 the	 contrary	 to	 its	 PCS	 subcategory	 as	 mentioned	 above,	 there	 was	 no	













The	 relationship	 between	 apelin	 levels	 and	 WOMAC	 results	 was	 investigated	 using	























The	relationship	between	apelin	 levels	and	other	 joints	 involved	with	OA	was	 investigated	
using	Spearman’s	correlation.	There	was	no	statistically	significant	correlation	seen	between	











The	 relationship	 between	 apelin	 levels	 and	 upper	 limb	 joint	 OA	 was	 investigated	 using	












The	 relationship	 between	 apelin	 levels	 and	 leptin	 concentration	 was	 investigated	 using	
Spearman’s	 correlation.	 There	was	no	 statistically	 significant	 correlation	between	 the	 two	
variables	in	general,	rs	=	-0.136,	n	=	114,	p	=	0.149.	However,	further	analyses	looking	at	the	
relationship	 between	 apelin	 levels	 and	 each	 subgroup’s	 leptin	 concentrations	 showed	 a	
medium	negative	correlation	between	apelin	levels	and	Non	obese	apelin	levels,	rs	=	-0.325,	





































































































The	 relationship	 between	 progranulin	 levels	 and	 PCS	 for	 SF12	 was	 investigated	 using	
Spearman’s	 correlation.	 There	was	no	 statistically	 significant	 correlation	between	 the	 two	
variables	in	general,	rs	=	0.170,	n	=	114,	p	=	0.070.	However,	further	analyses	looking	at	the	
relationship	 between	 progranulin	 levels	 and	 each	 gender’s	 PCS	 results	 showed	 a	 small	
positive	correlation	between	PCS	and	progranulin	 levels	 in	females,	rs	=	0.288,	n	=	57,	p	=	























The	 relationship	 between	 progranulin	 levels	 and	 WOMAC	 was	 investigated	 using	
Spearman’s	 correlation.	 There	 was	 no	 statistically	 significant	 correlation	 seen	 between	
apelin	 levels	and	all	groups.	However,	on	 further	analysis,	a	medium	negative	correlation	












correlation.	 There	was	no	 statistically	 significant	 correlation	between	 the	 two	variables	 in	
general,	rs	=	-0.068,	n	=	114,	p	=	0.475.	However,	further	analyses	looking	at	the	relationship	
between	 progranulin	 levels	 and	 each	 gender’s	 PCS	 results	 showed	 a	medium	 negative	
correlation	between	KL	scale	and	progranulin	levels	in	males,	rs	=	-0.351,	n	=	57,	p	=	0.007.	





































































































The	 relationship	 between	 progranulin	 levels	 and	 S1008/A9	 was	 investigated	 using	
Spearman’s	correlation.	There	was	a	small	negative	correlation	between	the	two	variables,	
rs	 =	 -0.222,	 n	 =	 114,	 p	 =	 0.018.	 Further	 analyses	 looking	 at	 the	 relationship	 between	
progranulin	 levels	 and	 each	 subgroup’s	 S1008/A9	 results	 showed	 a	 medium	 negative	
correlation	between	S1008/A9	and	obese	progranulin	levels,	rs	=	-0.375,	n	=	38,	p	=	0.021.	
Similarly,	 looking	 at	 gender	 category,	 female	 progranulin	 levels	 had	 a	 small	 negative	






Variable	 Non	Obese	(G1)	 Obese	(G2)	 MetS	(G3)	 Significance	
(p<0.05)	
Age	 74.00	 62.00	 71.50	 G1>G2	
G2<G3	
BMI	 23.00	 33.00	 34.00	 G1<G2	
G1<G3	
MCS	 63.75	 59.35	 60.90	 G1>G2	
Leptin	 6.59	 39.24	 30.42	 G1<G2	
G1<G3	
Apelin	 1.64	 1.50	 1.71	 Not	sig	





Variable	 Female	(F)	 Male	(M)	 Significance	
(p<0.05)	
Upper	limb	OA	 42.11%	 14.04%	 F>M	
Leptin	 39.07	 16.25	 F>M	
Monocytes	 0.6	 0.7	 F<M	







Age	 -0.222	 0.112	 -0.040	 0.126	 All	only	
BMI	 0.681	 0.079	 0.350	 0.418	 All,	G2,	G3	
PCS	 -0.094	 -0.369	 0.023	 -0.134	 G1	only	
MCS	 -0.299	 -0.126	 -0.219	 -0.266	 All	only	
SF12	 -0.350	 -0.345	 -0.171	 -0.384	 All,	G1,	G3	
S100A8/A9	 0.289	 0.234	 0.270	 0.424	 All,	G3	
	
Table	9	Statistically	significant	results	in	gender	correlation	for	Leptin	
Variable	 All	 Female	(F)	 Male	(M)	 Significance	
(p<0.05)	
Age	 -0.222	 -0.312	 -0.288	 All	variables	
BMI	 0.681	 0.721	 0.743	 All	variables	
MCS	 -0.299	 -0.431	 -0.080	 All,	F	
SF12	 -0.350	 -0.380	 -0.255	 All,	F	







Age	 -0.085	 -0.358	 -0.093	 -0.181	 G1	
PCS	 0.311	 0.379	 0.357	 0.245	 All,	G1,	G2	





Variable	 All	 Female	(F)	 Male	(M)	 Significance	
(p<0.05)	







Upper	limb	OA	 -0.088	 0.099	 -0.368	 -0.039	 G2	
S100A8/A9	 -0.222	 -0.078	 -0.375	 -0.216	 All,	G2	
	
Table	13	Statistically	significant	results	in	gender	correlation	for	Progranulin	
Variable	 All	 Female	(F)	 Male	(M)	 Significance	
(p<0.05)	
PCS	 0.170	 0.288	 0.055	 F	only	
WOMAC	 -0.168	 0.109	 -0.434	 M	only	
KL	scale	 -0.168	 -0.109	 -0.434	 M	only	









participants	were	 then	categorised	 into	non-obese,	obese	and	MetS	using	 the	world-wide	











evolution	of	 time	and	 fitness	 for	operation,	when	patients	 together	with	 clinicians,	 finally	
decide	to	proceed	with	surgical	intervention.		
	
Those	with	 normal	 BMI	were	 able	 to	 persevere,	 as	much	 as	 possible,	with	 non-operative	
management	for	their	knee	OA	until	later	in	life	while	obese	individuals	without	MetS,	one	
presented	 at	 a	 younger	 age	 for	 surgical	 procedures,	 perhaps	 because	 they	were	 clinically	
more	disabled.	The	young	obese	scored	the	lowest	for	MCS	and	second	lowest	for	SF12	and	







diagnosed	with	 these	medical	problems,	however,	 their	elective	 surgical	 treatment	would	
tend	to	be	delayed.	This	is	because	they	need	time	to	be	therapeutically	stabilised	first	with	
multiple	 adjustments	 of	 their	 medical	 treatment,	 such	 as	 optimising	 the	 dosage	 of	 their	









Other	 studies	 concurred	 with	 our	 findings.	 In	 a	 paper	 conducted	 by	 Ku	 JH	 et	 al,	 they	
reported	a	mean	age	of	70.1	years	in	patients	who	had	a	mean	BMI	of	26.1	and	undergoing	
total	knee	arthroplasty	(242).	Another	study	also	found	that	their	participants	had	a	mean	
age	of	61.4	 years	 for	males	and	64.7	 years	 for	 females	with	mean	BMIs	of	28.7	and	32.5	
respectively	(243).	Our	study	is	the	first	to	characterise	the	mean	and	median	age	of	MetS	







decide	 the	 most	 appropriate	 treatment.	 To	 that	 end,	 we	 have	 utilised	 PROMS	 to	 help	
quantify	patients’	 severity.	 Looking	at	WOMAC	score,	 there	was	no	 statistically	 significant	
difference	between	the	three	groups.	This	indicates	that	all	of	the	knee	OA	patients	suffered	









59.35)	and	MetS	group	 (Md	=	60.90).	As	 for	 its	counterpart,	PCS	scores	did	not	show	any	
significant	 difference	 across	 the	 groups.	 These	 results	 suggest	 that	 being	 obese	 or/and	
having	medical	conditions	can	greatly	affect	the	patients’	overall	mental	health.	Ayyar	et	al	
reported	similar	result	trends	to	our	study	whereby	non	obese	group	had	a	lower	mean	PCS	
score	 of	 28.8	whilst	 the	 obese	 participants	 had	 a	 slightly	 higher	mean	 PCS	 score	 of	 30.0.	
Moreover,	they	also	reported	a	downward	pattern	for	MCS	scores	between	non	obese	and	
obese	subjects	 (mean	score	of	51.1	vs	48.3)	 (244).	Another	study,	published	 in	 the	British	
Journal	of	Bone	and	Joint	Surgery	in	2010,	recruited	over	500	participants	and	did	not	show	





Our	 study	 did	 not	 find	 any	 meaningful	 difference	 amongst	 the	 groups	 on	 their	WOMAC	
scores	and	this	is	in	good	agreement	with	Gandhi	et	al	who	looked	at	pre-operative	WOMAC	










impaired	 by	 OA	 aside	 from	 their	 knee	 joints	 need	 to	 be	 gauged	 whether	 that	 particular	











age	 is	 an	 independent	 risk	 factor	 for	 the	 development	 of	 OA	 i.e.	 non	 obese	 group	 was	
confounded	by	age	(247).		
	
E	 Yusuf	 et	 al	 conducted	 a	 systematic	 review	 on	 a	 series	 of	 observational	 projects	 and	
strongly	 supported	 the	 positive	 relationship	 between	 BMI	 and	 OA	 involvement	 in	 other	
joints,	 especially	 in	 the	 hands	 (17).	 Consistently,	 comparing	 with	 non	 obese	 subjects,	
individuals	with	BMI	of	25-30	had	a	3	times	higher	odds	whereas	those	with	BMI	of	30-35	
had	 a	 5	 times	 higher	 odds	 of	 suffering	 from	 spinal	 facet	 joints	 OA	 (248).	 Shoulder	 joints	













There	 are	 many	 theories	 that	 have	 been	 proposed	 in	 the	 literature	 pertaining	 to	 pain	













genders	 were	 still	 within	 their	 normal	 ranges.	 This	 can	 be	 interpreted	 that	 circulating	
inflammatory	 cells	 are	 not	 elevated	 thus	 implying	 towards	 more	 of	 a	 focused,	 localised	




Another	 intriguing	 result	discovered	 in	 this	 research	was	a	 statistically	 significant	 levels	of	
S100A8/A9	 in	 female	 subjects	 than	 in	males	 (5.41	 vs	 3.88).	 This	 could	mean	 that	 higher	
concentration	of	circulating	DAMPs	were	present	 in	women	that	can	promote/amplify	the	
innate	immunity	leading	to	inflammation.	We	believe,	we	are	the	first	to	describe	a	distinct	









Assimilating	 the	 baseline	 patient	 data	 into	 our	 primary	 objective,	 we	 found	 several	
statistically	 significant	changes	among	 the	3	 investigated	groups.	Circulating	plasma	 leptin	
was	detected	to	be	at	its	lowest	level	in	the	non	obese	group	(Md	=	6.59)	followed	by	MetS	
subjects	(Md	=	30.42)	and	the	highest	seen	in	obese	patients	(Md	=	39.24)	(see	Table	14	&	
Table	 15	 on	 page	 158	 &	 159).	 Likewise,	 leptin	 concentration	 was	 remarkably	 higher	 in	
females	(Md	=	39.07)	than	males	(Md	=	23.71).	However,	no	statistical	difference	was	noted	
between	obese	and	MetS	patients	with	regards	to	their	leptin	levels.	Our	findings	concurred	
with	 previous	 studies	 that	 looked	 at	 this	 adipokine	 amongst	 knee	 osteoarthritic	 subjects	
(230,	238,	254,	255).	The	clinical	features	observed,	both	physically	and	mentally,	in	younger	





and	 found	 no	 statistically	 significant	 difference	 between	 them.	 Likewise,	 similar	 findings	
were	 revealed	 between	 gender.	 This	 evidence	 could	 imply	 that	 these	 circulating	 plasma	
adipokines	did	not	change	with	 increasing	excess	 fatty	 tissues	 (increasing	BMI)	 suggesting	
that	 perhaps	 these	 adipokines,	 that	 contribute	 to	 joint	 damage,	 could	 derive	 from	 local	
dissemination	(around/within	the	joint)	rather	than	from	systemic	origin.		
	
Looking	 into	 the	 literature,	 our	 study	 is	 thus	 far,	 the	 first	 one	 to	 describe	 plasma	 apelin	
concentrations	in	patients	with	end	stage	knee	osteoarthritis	with	variable	BMIs.	Ju	Z	et	al	
explored	 the	 changes	 seen	 in	 80	 early	 OA	 knee	 participants	 and	 reported	 a	 decrease	 in	
apelin	 level	 along	 with	 TNF	 alpha	 when	 they	 were	 exposed	 to	 electro-acupuncture	
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treatment	(256).	Unlike	our	case	(which	we	will	mentioned	later	under	correlation	of	apelin	
with	 other	 parameters),	 they	 considered	 apelin	 to	 have	 a	 pro-inflammatory	 capability	
analogous	to	the	action	seen	in	TNF	alpha.	A	separate	study	 investigated	concentration	of	
apelin	in	healthy	subjects	and	knee	osteoarthritic	adults;	they	also	noted	higher	apelin	levels	
in	 serum	 and	 synovial	 fluid	 for	 the	 latter	 group	 (187).	 However,	 our	 study	 specifically	
explored	 whether	 there	 were	 any	 differences	 in	 the	 systemic	 apelin	 concentration	 in	
patients	 with	 established,	 end	 stage	 knee	 OA	 with	 contrasting	 BMI	 levels	 and	 the	
presence/absence	of	co	morbidities;	showing	no	difference	in	its	level.	
	





with	 OA	 and	 found	 higher	 PGRN	 concentration	 in	 RA	 and	 OA	 individuals	 compared	 to	













as	 their	 blood	 parameters	 with	 regards	 to	 gender.	 As	 mentioned	 earlier,	 statistically	
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significant	difference	were	seen	under	the	categories	of	upper	limb	joints	involved	with	OA,	
leptin	 level	 and	 S100A8/A9	 concentration	 (see	 Table	 16	&	 Table	 17	 on	 page	 160	&	 161).	
These	 findings	might	 indicate	 that	 females,	 with	more	 overall	 fat	 content	 and	 deposited	
more	 peripherally	 (pear	 shaped),	 produced	 higher	 plasma	 adipokine	 leptin	 together	with	
S100A8/A9	proteins.	Therefore,	solely	or	with	the	combination	of	the	two	pro-inflammatory	
factors,	 they	 had	 the	 potential	 to	 promote	 inflammation	 in	 synovial	 joints	 which	
consequently	 led	 to	 faster	 progression	 of	 OA.	 Karvonen-Gutierrez	 et	 al	 agreed	 with	 our	
findings	 where	 higher	 leptin	 levels	 were	 seen	 in	 female	 patients	 with	 cardio-metabolic	
characteristics	 than	 males	 (258).	 They	 also	 reported	 higher	 prevalence	 of	 osteophytes-
defined	 radiographic	 knee	OA	 in	obese	participants	 than	 the	non	obese	people.	 Similarly,	






























Analysing	 the	 clinical	 parameters,	 leptin	 level	 was	 reported	 to	 have	 a	 strong	 positive	
correlation	with	BMI	 (rs	 =	 0.681,	 p	 <	 0.001).	 This	was	 followed	by	 an	 inverse	 relationship	
with	MCS	(rs	=	-0.299,	p	=	0.001)	and	overall	SF12	(rs	=	-0.350,	p	<	0.001)	(see	Table	18	on	
page	 162).	 On	 further	 assessment	 of	 the	 subgroups,	 females	 had	 more	 pronounced	





and	 reported	a	positive	correlation	with	 increasing	OA	severity	 (rs	=	0.23,	p	<	0.05)	 (259).	
Other	 studies	 demonstrated	 the	 connection	between	higher	 BMI	 and	 knee	 joints	OA	 and	
increasing	 serum	 leptin	 levels	 (238,	 254).	Messengale	et	al	 studied	hand	OA	patients	 and	
noted	 positive	 relationship	 between	 serum	 leptin	 and	 severity	 of	 pain	 but	 not	 with	
radiographic	changes	(260).	 Interestingly,	Lubbeke	et	al	also	observed	a	strong	correlation	
of	 serum	 leptin	 to	 its	 synovial	 fluid	concentration	 in	participants	with	end	stage	knee	and	
hip	OA	and	recorded	significant	decrease	in	the	PCS,	MCS	as	well	as	WOMAC	scores	(261).	
	
Within	 blood	 plasma	 variables,	 S100A8/A9	 was	 found	 to	 be	 significantly	 associated	 with	
leptin	levels	(rs	=	0.289,	p	<	0.002)	(see	Figure	28	on	page	81).	We	believe	that	our	study	is	
the	 first	 to	 describe	 this	 correlation	 in	 knee	 OA	 patients.	 This	 could	 be	 interpreted	 that	
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increasing	DAMPs	along	with	higher	leptin	concentration	secondary	to	excess	adipose	tissue	





With	 regards	 to	 other	 blood	 parameters	 such	 as	 white	 blood	 cells,	 neutrophils	 and	
monocytes	 counts,	 they	 had	 negligible	 correlation	 with	 leptin	 and	 did	 not	 reach	 any	
significance.	 This	 confirms	 our	 speculation	 that	 OA	 does	 not	 noticeably	 involve	 systemic	

















that	 circulating	 apelin	 was	 independent	 of	 any	 changes	 observed	 in	 these	 parameters.	
Correspondingly,	when	apelin	was	independent	to	all	of	the	blood	plasma	variables	except	
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leptin	 whereby	 a	 medium	 negative	 correlation	 was	 demonstrated	 between	 the	 two	
variables	in	non	obese	group	(see	Figure	36	on	page	89).	
	
Combining	 our	 overall	 results,	 the	 data	 suggest	 that	 systemic	 plasma	 apelin	 appears	 to	
perform	 more	 of	 an	 anti-inflammatory	 role	 rather	 than	 pro-inflammatory	 function.	 As	
mentioned	 earlier	 in	 our	 literature	 review	 section,	 apelin	 has	 been	 known	 to	 have	 anti-












human	 cartilage	 supporting	 its	 anti-inflammatory	 property	 (33,	 202-204).	 This	 might	 be	
indicated	 by	 higher	 functional	 scores	 or	 reduced	 joint	 damage.	 Indeed,	 increasing	
concentration	 of	 circulating	 plasma	 PGRN	was	 associated	with	 rising	 PCS	 scores	 (females	
only);	reducing	WOMAC	scores	as	well	as	less	radiographical	evidence	of	knee	joint	damage	


































The	 design	 of	 AdipOA	 study	 included	 collecting	 and	 correlating	 details	 of	 relevant	 clinical	
and	laboratory	data	as	suggested	by	a	review	of	numerous	papers	pertaining	to	adipokines	
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all	 the	 information	on	their	baseline	pre-operative	blood	tests	as	well	as	 their	 radiological	
findings	based	on	KL	scale.	We	have	selected	participants	who	were	of	Caucasian	origin	and	
this	would	help	us	exclude	the	influence	of	genetic	variability	in	our	study.	Moreover,	equal	
number	 of	 participants	 in	 the	 gender	 category	 was	 recruited	 for	 each	 investigated	









to	 attain	 and	 demonstrate	 enough	 power	 in	 the	 study.	We	 also	 applied	 the	 appropriate	














an	 age	matched	 participants	 in	 the	 obese	 and	MetS	 groups	who	were	 as	 old	 as	 the	 non	
obese	 group.	 Ideally,	 to	 minimise	 this	 setback	 is	 to	 carry	 out	 a	 blinded,	 randomised	
controlled	trial.		
	




participants	 who	 had	 end	 stage	 primary	 knee	 OA	 but	 chose	 not	 to	 have	 any	 operation.	







OA	 is	 debatable	 even	 up	 to	 a	 level	 where	 some	 researchers	 think	 it	 has	 a	 contradictory	







They	were	 taking	 these	prescriptions	as	part	of	 the	medical	management	of	 their	OA	e.g.	
non-steroidal	anti-inflammatory	drugs,	or/and	to	control	 their	cardio-metabolic	conditions	
e.g.	medications	for	hypertension/	diabetes	mellitus/	abnormal	lipid	profile.	The	possibility	
of	 their	 actions	 on	 the	 systemic	 adipokines	 production	 as	 well	 as	 its	 effect	 on	 cartilage	




in	 a	 blinded	 procedure.	 It	was	 assessed	 solely	 by	 the	main	 author	 using	 the	 participants’	
anonymous	 study	 identification	 number.	 Therefore,	 the	 results	 could	 be	 prone	 to	
inaccuracies	and	assessor’s	bias.		
	
Once	 the	 whole	 data	 were	 obtained,	 we	 identified	 a	 number	 of	 outliers	 in	 the	 results	















The	 research	 work	 can	 be	 extended	 by	 investigating	 the	 synovial	 fluid	 concentration	 of	
these	 adipokines	 and	 correlate	 them	with	 the	 circulating	 plasma	 levels.	 Since	 our	 results	
showed	negligible	 correlation	between	plasma	 apelin	 and	PGRN,	 by	 exploring	 its	 synovial	
fluid	content	would	provide	us	more	information	whether	they	contribute	any	effort	in	the	
pathophysiology	of	OA.	 If	 they	are,	 this	means	 that	 those	molecules	 could	originate	 from	
local	dissemination	rather	that	systemic	origin.		
	










Human	 genetic	 makeup	 plays	 a	 big	 role	 behind	 the	 formation	 and	 progression	 of	 this	
disease.	It	does	not	commonly	follow	the	typical	mendelian	inheritance	but	it	 is	 likely	that	
multiple	 genes	 are	 interacting	with	 each	 other	 as	 opposed	 to	 a	 single	 gene	 defect	 (271).	
Indeed,	different	ethnic	group	will	have	a	substantial	variation	in	the	genetic	backgrounds.	
Therefore,	one	could	assume	that	the	adipokines	secreted	would	be	behaving	differently	as	
well	 (272).	There	 is	a	multitude	evidence	 in	 the	 literature	 investigating	 the	relationship	of	
adipokines	 production	 and	 knee	 osteoarthritis	 in	 the	 Caucasian	 population	 with	 obesity.	
However,	 little	evidence	 is	 available	on	how	 they	operate	or	behave	 in	a	population	with	
different	 ethnicity.	 Thus,	 it	would	 be	 interesting	 to	 extend	 the	 arm	of	 this	 research	work	






266),	 practicing	 healthy	 lifestyle	 such	 as	 giving	 up	 on	 smoking	 and	 alcohol	 consumption	
could	be	a	 rewarding	study	 to	 look	 into.	By	cutting	out	 tobacco	and	alcohol,	 this	will	also	
eliminate	 the	ROS	 load	 in	 the	body	 (273,	274).	Similarly,	promoting	weight	 loss	as	part	of	
non	operative	treatment	is	also	a	viable	option.	In	recent	years,	many	studies	have	evidence	
to	verify	alteration	in	adipokines	levels	when	obese,	knee	OA	participants	were	exposed	to	
either	a	dietary	control	or	an	exercise	 regime	or	a	combination	of	both	 leading	 to	weight	
loss	 (275,	 276).	 Indeed,	 both	 of	 these	 factors	 can	 reduce	 the	 impact	 of	MetS	 onto	 their	








society	 and	 the	 economy	 worldwide.	 The	 current	 concept	 suggests	 that	 adipokines,	
produced	 by	 excess	 adipose	 tissue,	 can	 trigger	 low	 grade	 inflammation	 leading	 to	 OA.	
AdipOA	 study	 has	 illustrated	 the	 important	 interactions	 of	 adipokines	 in	 this	 respect.	We	








by	WOMAC.	 However,	 non	 obese	 patients	 were	mentally	 ‘healthier’	 compared	 to	
the	other	two	groups	when	assessed	using	SF12.	
	




the	 lowest	 in	the	non	obese	group.	Additionally,	 female	participants	showed	much	
higher	leptin	levels	than	males.		
	
• Moreover,	 leptin	 displayed	 a	 strong	 positive	 correlation	 with	 BMI	 and	 modest	




• Apelin	 did	 not	 show	 any	 statistical	 difference	 between	 the	 investigated	 groups.	
However,	 our	 results	 revealed	 medium	 positive	 correlation	 with	 PCS	 for	 SF12	






(females	 only)	 and	 small	 negative	 correlation	 with	WOMAC	 and	 KL	 scale	 in	 male	
subjects	only.	
	
• S100A8/A9	 was	 found	 to	 be	 significantly	 higher	 in	 females	 than	males	 and	 has	 a	
small	positive	relationship	with	increasing	leptin	level	across	all	participants.	
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National Research Ethics Service 
 
NRES Committee North West - Liverpool Central 
3rd Floor 
Barlow House 





09 September 2015 
 
Prof Simon P Frostick 
University of Liverpool 
Department of Molecular and Clinical Cancer Medicine 





Dear Prof Frostick 
 
Title of the Research Tissue Bank: Liverpool Musculoskeletal Biobank 
REC reference: 15/NW/0661 
Designated Individual: Dr Janet Risk 
IRAS project ID: 182091 
 
The Research Ethics Committee reviewed the above application at the meeting held on 02 
September 2015. The Committee thanks Amanda Wood and Joseph Alsousou for attending to 
discuss the application. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter.  The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact the REC Manager 
Mrs Carol Ebenezer, nrescommittee.northwest-liverpoolcentral@nhs.net. 
Under very limited circumstances (e.g. for student research which has received an 




The members of the Committee present gave a favourable ethical opinion of the above research 
tissue bank on the basis described in the application form and supporting documentation, 
subject to the conditions specified below.  
 
The Committee has also confirmed that the favourable ethical opinion applies to all research 
projects conducted in the UK using tissue or data supplied by the tissue bank, provided that the 
release of the tissue or data complies with the attached conditions. It will not be necessary for 
these researchers to make project-based applications for ethical approval. They will be deemed 
to have ethical approval from this committee. You should provide the researcher with a copy of 


















COLLECTION AND STORAGE OF 
TISSUE, BLOOD AND OTHER 










Contact Information for Liverpool Musculoskeletal Biobank 
The LMB Bank Manager,  
Professor Simon P Frostick (Professor of Orthopaedic Surgery) 
Or Mr Joseph Alsousou   
Musculoskeletal Science Research Group, 
Division of Surgery and Oncology, 
Royal Liverpool University Hospital, 




We would like to invite you to take part in a research study.   Before you 
decide whether to take part you need to understand why the research is being 
done and what it will involve.   Please take time to read the following information 
carefully and discuss it with others if you wish. 
	
What is the Liverpool Musculoskeletal Biobank (LMB)? 
The Liverpool Musculoskeletal Biobank (LMB) works closely with local hospitals to 
collect and store tissue, blood and biological samples for use in medical and 
scientific research.   By doing this the LMB will be able to build a valuable 
collection which will be used by research groups investigating the causes, 
development and treatment of musculoskeletal diseases.    It is hoped that the 
resulting knowledge will help other patients in the future. 
	
Why have I been chosen? 
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Your hospital has agreed to help the LMB collect samples from its patients. Either, 
you are about to undergo a surgical operation or biopsy procedure, which will 
involve the removal of pieces of tissue as a part of your s tandard  treatment. 
Or, you will be asked to give a biological sample as part of your routine 
appointment. We are asking for your consent for the samples to be stored and 
used later in research. 
	
What will happen if I choose to take part? 
The musculoskeletal tissue (bone, joint, ligaments, tendon, blood or bone 
marrow) removed at your surgical operation is in most cases discarded or 
destroyed after your standard procedure.  
	
If you agree to take part in this study, we are asking for your informed consent to 
store some of this tissue in the LMB for use in research projects. The tissue 
sample the LMB will store will include all tissues removed during your operation or 
procedure. And we will ask your consent to complete disease related 
questionnaires. This will allow researchers to assess the relationship between 
tissue changes and symptoms. The data will be anonymised before linking it to the 
tissue samples.  
	
As part of your treatment, a doctor will normally take a routine blood sample. We 
would like your informed consent to take a small additional amount at the same 
time as this routine sample. This will usually be taken at the time of your admission 
or surgery and will be approximately 50ml, around 10 teaspoons worth.  This 
sample will be beneficial for current and future research purposes. We would store 
this together with the tissue and blood sample. 
	
We would also like your consent to access your health records. These will be 
reviewed by LMB staff on an annual basis in order to update information on the 
Tissue Bank database. All information will be treated with the strictest 
confidence and held securely within the LMB. 
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In addition, the LMB would seek to access information held by other sources such 
as NHS Trusts, Disease Registries (such as the National Joint Registry). This 
information is essential to help researchers understand what your illness was like  
and  relate  what  is  found  in  the  laboratory  to  what  happens  to patients. Your 
name, address and any other personal data will be removed before any 
information is given to research groups, so you will not be identifiable to the 
researchers. 
 
What are the advantages and disadvantages of taking part? 
The samples taken for the research project will only be taken once the necessary 
diagnostic tests have been performed.   The results of research carried out using 
your tissue, blood and/or biological samples, and those of others, may help in the 
future discovery of new drugs and treatments for patients with a variety of 
conditions. 
	
There will be no direct benefit to yourself as you will not be identifiable to the 
research team. 
	
There will be no additional risks if you choose to participate. The risks associated 
with surgery will be explained separately by the medical team as part of your 
standard treatment. 
	
When the blood sample is taken, occasionally, this may require an additional entry 
site to the routine blood sample. On the small number of occasions that this may 
occur, there is the small chance you may experience some bruising at the site. 
This will not exceed routine blood sampling bruising.  
	
Do I have to take part? 
It is up to you to decide whether or not to allow us to collect samples of your 
tissue, blood and/or other biological samples.  If you do decide to take part, then 
you can keep this information booklet and you will be asked to sign an informed 
consent form.  A copy of what the consent form will look like can be found in the 
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“Notes” at the back of this document. If you decide not to take part, you do not 
need to give a reason. 
 
Whatever your decision it will not affect the standard of care that you receive. 
	
What will happen if I change my mind? 
If you do decide to take part, you are still free to change your mind at any time. 
You have the right to withdraw your consent to store your tissue, blood and/or 
biological samples without giving a reason.  If you do withdraw, then it will not 
affect in any way the treatment that you are receiving. You can withdraw your 
consent by using the contact details found at the front of this booklet by contacting 
the Tissue Bank Manager. 
	
The tissue, blood and/or biological samples stored in the LMB, along with any 
information held about you, will be destroyed and a letter of confirmation will be 
sent to you.  
 
If you change your mind a long time after the samples were donated, then some 
research may have already taken place on your samples. The LMB would not be 
able to recall samples and information once they have been used, but the LMB 
would request the return of any unused samples for adequate disposal. This would 
ensure that no further research work will be undertaken on your tissue, blood 
and/or biological samples. 
	
What will happen to my tissue or blood? 
Research groups will be able to use your gift of tissue, blood and/or biological 
samples to understand the causes of a particular disease and to improve 
treatment and care for patients in the future. Your tissue, blood and/or biological 
samples will not be used for transplantation or reproductive cloning.   Nor will the 




The research may be carried out in Academic Institutions, the NHS or 
collaborating research institutes involved in medical research worldwide.  In all 
cases, you will be anonymous to the researcher. 
	
When we store samples we will use some of them to perform a genetic 
assessment to obtain genetic material (DNA, RNA and protein).   We are asking 
you to allow us to obtain DNA, RNA and protein so that this can also be made 
available to research groups.  We will not use DNA; RNA or protein samples for 
any purpose other than research and the research team will not be able to 
identify you in any way. 
	
What if researchers find new information about my condition? 
Usually the information discovered during research will not have any implications 
for you personally and will not be relevant to your future care and treatment. 
However, in the unlikely event of finding abnormal results, we will inform the doctor 
in charge of your care who will arrange for you to be seen accordingly.  
	
Will anybody make a profit from my tissue, blood and/or biological samples? 
You are asked to donate your tissue, blood and/or biological samples for research 
as a gift and will not receive a financial reward either now or in the future.  The 
LMB will not sell your tissue, blood and/or biological samples for profit to other 
researchers.  A charge will be made by the LMB to researchers only to cover 
processing and staff costs.  However, your tissue, blood and/or biological samples 
may be used in a research project that may lead to the development of new drugs 
or treatments.   It will not be possible for you to make a claim for money as you 
will be waiving all commercial rights relating to the samples you donate.  Any 
drug, treatment or test developed may help all of us in the future. 
	
What will happen to the results of the research study? 
Research studies using tissue, blood and/or biological samples may take 
several years to complete. Results will be published when appropriate in scientific 
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papers and magazines and at scientific meetings. The LMB will request updates 
on the progress of research projects. 
	
You will not be able to be identified if research using your tissue, blood and/or 
biological samples is published in any scientific papers. 
 
Will my taking part in this study be kept confidential? 
All information that is collected related to your medical condition will be kept strictly 
confidential. Your name, address and other personal information will be 
removed before any information is released to researchers using your tissue, 
blood and/or biological samples. You will not be able to be identified by the 
researcher. 
	
Who has reviewed the study? 
The collection and storage of tissue and blood by the LMB has been ethically 
approved by the NHS Research Ethics Service, an independent body external to 












PARTICIPANT NAME:  
PARTICIPANT DOB:  
If you decide to withdraw your consent for whatever reason, please indicate which consent you wish 
to withdraw by initialling the appropriate box/boxes below. Please send the top copy of this form in 
the stamped addressed envelope provided. The bottom copy is for your own record.  
Withdrawing your consent will mean that your tissue samples and/or clinical data will not be made 
available in the future to anyone wishing to carry out analyses/research studies. Your tissue will be 
destroyed and where ever possible any related data accrued from your material will be removed.  
A. TISSUE  
I withdraw my consent for the use of my tissue by the Liverpool Musculoskeletal 
Biobank (LMB) for any research project taking place now or in the future, and 
where possible I wish for my genetic data to be removed from any database.  
B. ACCESS TO CLINICAL DATA AND IMAGING STUDIES  
I withdraw my consent for access to my clinical notes and/or imaging for the 




























3. Wash	 Buffer	 –	 (Wash	 Buffer	 Concentrate	 comes	 in	 21	 ml/vial	 of	 a	 25	 fold	













500	 microlitres	 of	 Calibrator	 Diluent	 RD5P	 into	 each	 of	 the	 remaining	 tubes.	 Mix	
	 144	
each	 tube	 thoroughly	 before	 the	 next	 transfer.	 High	 standard	 will	 be	 1000	























Bring all reagents to room temperature before use.
Wash Buff er - If crystals have formed in the concentrate, warm to room temperature and mix 
gently until the crystals have completely dissolved. Add 20 mL of Wash Buff er Concentrate to 
deionized or distilled water to prepare 500 mL of Wash Buff er.
Substrate Solution - Color Reagents A and B should be mixed together in equal volumes 
within 15 minutes of use. Protect from light. 200 μL of the resultant mixture is required per well.
Calibrator Diluent RD5P (diluted 1:5) - Add 20 mL of Calibrator Diluent RD5P Concentrate to 
80 mL of deionized or distilled water to prepare 100 mL of Calibrator Diluent RD5P.
Human Leptin Standard - Refer to the vial label for reconstitution volume. Reconstitute 
the Human Leptin Standard with deionized or distilled water. This reconstitution produces a 
stock solution of 10,000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with 
gentle agitation prior to making dilutions.
Use polypropylene tubes. Pipette 900 μL of Calibrator Diluent RD5P into the 1000 pg/mL 
tube. Pi ette 500 μL of Calibrator Diluent RD5P into each of the remaining tubes. Use the stock 
solution to produce a dilution series (below). Mix each tube thoroughly before the next 
transfer. The 1000 pg/mL standard serves as the high standard. Calibrator Diluent RD5P serves 
as the zero standard (0 pg/mL).
100 µL Std.
10,000 pg/mL 1000 pg/mL 500 pg/mL 250 pg/mL 125 pg/mL 62.5 pg/mL 31.3 pg/mL 15.6 pg/mL





5. Add	 200	 microlitres	 of	 Human	 Leptin	 Conjugate	 to	 each	 well	 (Human	 Leptin	






7. Prepare	 Substrate	 Solution	 –	 (Colour	 Reagent	 A	 comes	 in	 12ml/vial	 of	 stabilized	








2	 N	 sulfuric	 acid).	 The	 colour	 will	 change	 from	 blue	 to	 yellow.	 Ensure	 thorough	
mixing.		
	














6. Substrate	 Solution	 should	 remain	 colourless	 until	 added	 to	 the	 plate.	 Keep	 Substrate	
Solution	 protected	 from	 light.	 Substrate	 Solution	 should	 change	 from	 colourless	 to	
gradations	of	blue.		
7. Stop	Solution	should	be	added	to	the	plate	in	the	same	order	as	the	Substrate	Solution.	
The	 colour	 developed	 in	 the	wells	will	 turn	 from	blue	 to	 yellow	 upon	 addition	 of	 the	























5. Label	 5	 tubes	with	 1500	 pg/ml,	 1000	 pg/ml,	 500	 pg/ml,	 250pg/ml	 and	 125	 pg/ml	
respectively.	Pipette	0.2	millilitres	of	Standard	Diluent	Buffer	into	the	first	two	tubes.	
Pipette	 0.3	millilitres	 of	 Standard	Diluent	 Buffer	 into	 each	of	 the	 remaining	 tubes.	
Add	0.4	millilitres	of	2250	pg/ml	standard	solution	into	1st	tube	and	mix	thoroughly.	
































































































10. Add	50	microlitres	of	Stop	Solution	 to	each	well	 (Stop	Solution	comes	 in	6ml/vial).	
The	colour	will	change	from	blue	to	yellow.	Ensure	thorough	mixing.		
	














6. Substrate	 Solution	 should	 remain	 colourless	 until	 added	 to	 the	 plate.	 Keep	 Substrate	
Solution	 protected	 from	 light.	 Substrate	 Solution	 should	 change	 from	 colourless	 to	
gradations	of	blue.		
7. Stop	Solution	should	be	added	to	the	plate	in	the	same	order	as	the	Substrate	Solution.	
The	 colour	 developed	 in	 the	wells	will	 turn	 from	blue	 to	 yellow	 upon	 addition	 of	 the	


















3. Wash	 Buffer	 –	 (Wash	 Buffer	 Concentrate	 comes	 in	 20	 ml/vial	 of	 a	 30	 fold	
concentrated	 solution).	 If	 crystals	 form	 in	 the	 concentrate,	 bring	 to	 room	




















































Standard	 S5	 S4	 S3	 S2	 S1	
800ng/ml	 400ng/ml	 200ng/ml	 100ng/ml	 50ng/ml	 25ng/ml	
	 153	
9. Add	50	microlitres	of	Stop	Solution	 to	each	well	 (Stop	Solution	comes	 in	6ml/vial).	
The	colour	will	change	from	blue	to	yellow.	Ensure	thorough	mixing.		
	













6. Substrate	 Solution	 should	 remain	 colourless	 until	 added	 to	 the	 plate.	 Keep	 Substrate	
Solution	 protected	 from	 light.	 Substrate	 Solution	 should	 change	 from	 colourless	 to	
gradations	of	blue.		
7. Stop	Solution	should	be	added	to	the	plate	in	the	same	order	as	the	Substrate	Solution.	
The	 colour	 developed	 in	 the	wells	will	 turn	 from	blue	 to	 yellow	 upon	 addition	 of	 the	


















Median	 Range	 Mean	 Standard	
Deviation	
Median	 Range	 Mean	 Standard	
Deviation	
Median	 Range	 Mean	 Standard	
Deviation	








PCS	 24.05	 	15.70-48.30		 27.03	 7.68	 25.35	 14.30-59.90	 27.95	 8.94	 23.90	 15.50-55.30	 26.86	 8.82	 Across	all	groups	:	p	>	0.05	a	
	




SF12	 88.95	 	58.50-110.40		 87.85	 11.68	 84.45	 42.20-104.40	 81.37	 13.00	 83.70	 57.70-116.00	 83.72	 12.91	 Across	all	groups	:	p	>	0.05	a	
	WOMAC	 46.02	 	10.61-78.03		 46.94	 15.57	 48.11	 15.91-96.00	 51.13	 21.86	 39.02	 13.64-100.00	 44.36	 18.83	 Across	all	groups	:	p	>	0.05	a	




Apelin	 1.64	 	0.40-2.63		 1.65	 0.50	 1.50	 0.86-2.61	 1.56	 0.42	 1.71	 0.82-2.58	 1.63	 0.45	 Across	all	groups	:	p	>	0.05	a	
	Progranulin	 28.15	 	12.60-90.32		 30.91	 13.29	 26.59	 13.93-331.68	 35.36	 50.11	 26.28	 13.78-211.49	 37.92	 40.88	 Across	all	groups	:	p	>	0.05	a	
	WBC	 8.45	 	4.30-16.30		 8.53	 2.36	 7.65	 4.40-16.30	 8.21	 2.57	 8.35	 4.50-13.50	 8.46	 2.26	 Across	all	groups	:	p	>	0.05	a	
	Neutrophils	 5.65	 	1.90-13.90		 5.81	 2.36	 4.70	 2.50-12.50	 5.36	 2.42	 4.95	 2.70-10.90	 5.67	 2.27	 Across	all	groups	:	p	>	0.05	a	
	Monocytes	 0.60	 	0.30-1.30		 0.68	 0.23	 0.65	 0.30-2.00	 0.72	 0.32	 0.70	 0.50-1.60	 0.77	 0.29	 Across	all	groups	:	p	>	0.05	a	
	S100A8/A9	 4.08	 	0.51-15.67		 4.92	 2.82	 5.08	 1.66-12.84	 5.52	 2.63	 3.97	 0.90-19.35	 4.60	 3.26	 Across	all	groups	:	p	>	0.05	a	
	






	 	 Non	obese	(G1,	n	=	38)	 Obese				(G2,	n	=	38)	 MetS						(G3,	n	=	38)	 p	value	
		 	 %	 %	 %	 		
	 Grade	2	 10.53	 10.53	 7.89	
p	>	0.05	a	
	
KL	scale	 Grade	3	 26.32	 42.11	 31.58	
Grade	4	 63.16	 47.37	 60.53	
other	joint	OA	 No	 47.37	 52.63	 39.47	
p	>	0.05	b	
	
Yes	 52.63	 47.37	 60.53	
upper	limb	OA	 No	 76.32	 81.58	 57.89	
p	>	0.05	b	
	










Median	 Range	 Mean	 Standard	Deviation	 Median	 Range	 Mean	 Standard	Deviation	 		
Age	 72.00	 45.00-91.00	 69.70	 11.11	 69.00	 44.00-84.00	 67.12	 9.59	 F	=	M	:	p	>	0.05	a	
BMI	 33.00	 20.00-39.00	 30.34	 5.70	 32.00	 22.00-40.28	 30.24	 4.87	 F	=	M	:	p	>	0.05	a	
PCS	 24.20	 15.50-59.90	 27.26	 8.43	 24.30	 14.30-55.30	 27.30	 8.52	 F	=	M	:	p	>	0.05	a	
MCS	 59.60	 19.40-72.30	 55.14	 12.58	 62.10	 29.10-72.30	 58.92	 11.46	 F	=	M	:	p	>	0.05	a	
SF12	 85.00	 42.20-106.50	 82.40	 12.58	 87.30	 57.70-116.00	 86.23	 12.68	 F	=	M	:	p	>	0.05	a	
WOMAC	 41.67	 10.61-84.85	 45.12	 18.30	 45.83	 13.64-100.00	 49.84	 19.49	 F	=	M	:	p	>	0.05	a	
Leptin	 39.07	 1.77-102.81	 41.11	 27.45	 16.25	 0.43-92.12	 19.81	 17.23	 F	>	M	:	p	<	0.001	b	
Apelin	 1.51	 0.40-2.63	 1.54	 0.47	 1.69	 0.79-2.60	 1.68	 0.43	 F	=	M	:	p	>	0.05	b	
Progranulin	 27.11	 12.60-211.49	 31.99	 26.92	 26.78	 13.78-331.68	 37.47	 46.45	 F	=	M	:	p	>	0.05	b	
WBC	 8.00	 4.30-14.50	 8.49	 2.52	 7.90	 4.50-16.30	 8.30	 2.26	 F	=	M	:	p	>	0.05	a	
Neutrophils	 5.10	 2.30-11.50	 5.86	 2.54	 5.00	 1.90-13.90	 5.37	 2.11	 F	=	M	:	p	>	0.05	a	
Monocytes	 0.60	 0.30-1.40	 0.66	 0.22	 0.70	 0.40-2.00	 0.79	 0.32	 F	<	M	:	p	<	0.05	a	













	 	 F	(n	=	57)	 M	(n	=	57)	 p	value	
		 	 %	 %	 		
	 Grade	2	 10.53	 8.77	
p	>	0.05	a	
	
KL	scale	 Grade	3	 36.84	 29.82	
Grade	4	 52.63	 61.40	













		 All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	











































	 All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	



























	 All	gender	(N	=	114)	 F	(n	=	57)	 M	(n	=	57)	 p	value	
Age	 -0.222	 -0.312	 -0.228	 Across	all	groups	:	p	<	0.05	a	
F	:	p	<	0.05	a		M	:	p	<	0.05	a	
BMI	 0.681	 0.721	 0.743	 Across	all	groups	:	p	<	0.001	a	
F	:	p	<	0.05	a		M	:	p	<	0.05	a	
PCS	 -0.094	 0.033	 -0.252	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
MCS	 -0.299	 -0.431	 -0.080	 Across	all	groups	:	p	=	0.001	a	
F	:	p	=	0.001	a		M	:	p	>	0.05	a	
SF12	 -0.350	 -0.380	 -0.255	 Across	all	groups	:	p	<	0.001	a	
F	:	p	<	0.01	a		M	:	p	>	0.05	a	
WOMAC	 -0.101	 -0.169	 0.048	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
KL	scale	 -0.021	 -0.093	 0.146	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Other	joint	OA	 0.074	 0.135	 -0.129	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Upper	limb	OA	 0.176	 0.095	 -0.028	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
WBC	 -0.075	 -0.152	 -0.048	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Neutrophils	 -0.085	 -0.159	 -0.092	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Monocytes	 -0.117	 -0.088	 -0.040	 Across	all	groups	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	








All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	










































All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	































All	gender	(N	=	114)	 F	(n	=	57)	 M	(n	=	57)	 p	value	
Age	 -0.085	 -0.088	 -0.081	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a			M	:	p	>	0.05	a	
BMI	 -0.051	 0.050	 -0.245	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a			M	:	p	>	0.05	a	
PCS	 0.311	 0.391	 0.215	 Across	all	gender	:	p	=	0.001	a	
F	:	p	<	0.01	a		M	:	p	>	0.05	a	
MCS	 -0.111	 -0.053	 -0.232	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
SF12	 0.064	 0.150	 -0.071	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
WOMAC	 0.080	 0.182	 -0.090	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
KL	scale	 0.115	 0.233	 -0.069	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Other	joint	OA	 0.130	 0.221	 0.110	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Upper	limb	OA	 0.067	 0.070	 0.246	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Leptin	 -0.136	 0.026	 -0.259	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
WBC	 -0.121	 -0.104	 -0.126	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Neutrophils	 -0.122	 -0.103	 -0.113	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Monocytes	 0.024	 0.001	 -0.035	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	








All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	










































All	groups	(N	=	114)	 Non	obese	(G1,	n	=	38)	 Obese	(G2,	n	=	38)	 MetS	(G3,	n	=	38)	 p	value	

































All	gender	(N	=	114)	 F	(n	=	57)	 M	(n	=	57)	 p	value	
Age	 0.008	 0.066	 -0.091	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
BMI	 -0.088	 -0.070	 -0.104	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
PCS	 0.170	 0.288	 0.055	 Across	all	gender	:	p	>	0.05	a	
F	:	p	<	0.05	a		M	:	p	>	0.05	a	
MCS	 0.009	 0.110	 -0.065	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
SF12	 0.070	 0.219	 -0.070	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
WOMAC	 -0.168	 0.109	 -0.434	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	=	0.001	a	
KL	scale	 -0.068	 0.213	 -0.351	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	<	0.01	a	
Other	joint	OA	 -0.102	 -0.146	 -0.072	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Upper	limb	OA	 -0.088	 -0.046	 -0.169	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Leptin	 -0.134	 -0.081	 -0.159	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Apelin	 0.134	 0.180	 0.098	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
WBC	 -0.121	 -0.104	 -0.126	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Neutrophils	 0.033	 -0.005	 0.083	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
Monocytes	 -0.051	 0.043	 -0.085	 Across	all	gender	:	p	>	0.05	a	
F	:	p	>	0.05	a		M	:	p	>	0.05	a	
S100A8/A9	 -0.222	 -0.280	 -0.155	 Across	all	gender	:	p	<	0.05	a	
F	:	p	<	0.05	a		M	:	p	>	0.05	a	
Note.	a	=	Spearman’s	rho	test
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